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advice procedures for human 
medicines co-ordinated by the 
HPRA
medical device economic 
operators registered with the 
HPRA – a significant increase on 
previous years
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MRP/DCP lead member state 
roles for the assessment of 
veterinary medicines
10
applications issued for clinical 
trials of human medicines
73







The HPRA was among the top ten 
contributors at EU level for lead 
assessment of centrally authorised 
human medicines & scientific advice
regulatory submissions made 
through the Common Electronic 
Submission Portal (CESP) managed 
by the HPRA
562,397  
export certificates issued – 1,019 
certificates for medicines and 2,520 




at a Glance 
good manufacturing practice 
(GMP) inspections at sites that 
produce human medicines or active 
substances 
63
the number of centrally 
authorised human medicines 
where the HPRA was EU 
rapporteur for aspects of safety 
monitoring and risk management
56
medical device vigilance reports 
received and assessed
1,668
market surveillance cases 
undertaken in respect of 
medical devices
dosage units of fake 




medicine recalls consisting of 
72 human medicines and 13 
veterinary medicines
85
reports of suspected adverse 
reactions associated with the use 
of veterinary medicines
391 
suspected adverse reaction 
reports for human medicines 
received
7,752  
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website users during the 




reactive surveillance cases 
initiated for cosmetic products
300 i
It gives me great pleasure to introduce the 
2020 Annual Report, which outlines the 
extensive work of the HPRA during what 
was a remarkably busy and challenging 
year for many reasons.  
COVID-19 and Brexit Response
In February 2020, Ireland saw its first official cases of 
COVID-19. As we know, the first nationwide lockdown 
soon followed in March and for the remainder of the 
year, Government would implement restrictions in a 
cyclical manner to protect public health as levels of 
disease in our communities continued to fluctuate. To 
complement the necessary public health guidelines, 
it was soon apparent safe and effective vaccines 
would be required to ultimately control the pandemic 
and limit the threat to public health. Within a year 
of the first reported cases of COVID-19, this had 
been achieved, enabling the initiation of national 
vaccination campaigns across Europe before year-
end. 
To move from the discovery of such a deadly virus 
to the development of safe and effective vaccines 
providing such significant levels of protection, within 
a year, is an incredible achievement. While it became 
possible due to a range of significant scientific 
developments and interventions, we must also 
recognise the importance of the adapted regulatory 
procedures to safely accelerate the authorisation of 
emergent vaccines. Committed experts from across 
the HPRA provided an exceptionally important 
public service through their contributions to both 
the national, and indeed European, COVID-19 
pandemic response. During the first wave of the 
pandemic at a national level, the HPRA worked 
tirelessly in partnership with the Department of 
Health, the Health Service Executive (HSE), healthcare 
professionals and industry stakeholders to minimise 
and proactively address any risks posed to the supply 
of medicines and medical devices to Irish patients. 
This partnership approach, developed in preparation 
for Brexit, delivered as intended and helped to ensure 
continued access to health products across the health 
system during a time of unprecedented demand 
internationally. 
I would like to acknowledge as well the success of 
the cohesive and strategic approach taken by the 
agency in response to the UK’s decision to leave the 
EU. Thanks to the very significant efforts of the HPRA 
at national and EU level, Ireland was able to maintain 
supplies of critical human and veterinary medicines, 
and medical devices into the country and avoiding 
the very real potential for disruption to supply 
presented by Brexit. Again, the HPRA’s engagement 
with key public health stakeholders demonstrates the 
importance of an integrated health system to deal 
with threats posed by significant external changes in 





Following the successful implementation and 
completion of the organisation’s last strategy from 
2016-2020, we look forward to the next period in 
development and advancement of the HPRA. Our 
new strategic plan sets out our ambition for the next 
five years beginning 2021 to deliver better outcomes 
for people and animals through value-driven 
regulation and partnerships. 
Building on our partnerships with others is a key 
theme of this five-year strategy. Significant and 
meaningful engagement with the broader health 
sector, and indeed patients, is central to our future 
effectiveness. Working with national agencies, 
professional bodies and patient groups can help us 
regulate more effectively taking into account the 
needs of the health system, while our input into 
relevant parts of the system can influence the safe use 
and availability of health products in clinical practice. 
The twin challenges of Brexit and COVID-19 have also 
demonstrated the need for, and value of, working 
collaboratively at a regional and global level. 
The strategy was progressed in a highly collaborative 
way, with development overseen by the Authority and 
the CE, but also involving staff, the statutory advisory 
committees and the organisation’s network of experts. 
External consultation also provided important 
feedback from many stakeholders, which helped 
guide the development of the plan. I believe the new 
strategy is suitably ambitious, comprehensive and 
representative of the needs of the many stakeholders 
served by the HPRA in its role as the national 
regulator of health products. 
  
Changes within the Authority 
Our commitment to succession planning aims to 
ensure the ongoing availability of the necessary 
knowledge, skills and technical competencies required 
at Authority level. We have seen the benefits of this 
work as we welcomed two new Authority members, 
Prof. Richard Reilly and Dr. Joe Collins. Both Richard 
and Joe are already contributing effectively to the 
Authority and have taken on the roles of chair to the 
advisory committees for medical devices and veterinary 
medicines, respectively. I believe the HPRA is well 
positioned to leverage from their vast knowledge and 
experience, which will complement the deep expertise 
of the current Authority members.
As my own term came to an end in December 
2020, so too did those of Profs. Caitriona O’Driscoll 
and David Kerins. Caitriona and I both joined the 
Authority in 2011 and I wish to pay tribute to her 
dedicated and expert service during this lengthy 
period. David joined the Authority in 2019 and 
immediately agreed to take the role of Chair of the 
Advisory Committee for Human Medicines, having 
already been an active contributor to the Committee 
for over 10 years. Both Caitriona and David gave 
generously of their vast knowledge and experience 
and I wish to thank them both for their huge 
contributions as valued members of the Authority.
In addition, I would like to take this opportunity 
to wish Mr. Michael Donnelly the very best of luck 
as he begins his tenure as Chairperson. It is an 
exciting period of growth and development for 
the organisation as the HPRA management team 
and staff, supported by the Authority, commences 
implementation of year one of the new strategy. 
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The members of the Management 
Committee in 2020 were:
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As always, it is a great pleasure to give my 
foreword to the HPRA’s annual report and 
to highlight the achievements of the year 
that has past.
COVID-19 Pandemic Response
The COVID-19 pandemic has affected almost every 
facet of life in 2020. Unfortunately, we have all 
seen harrowing stories of the devastating effects of 
COVID-19, but we have seen equally extraordinary 
and inspirational efforts of frontline healthcare 
workers – both here at home and across the world – 
to care for those suffering from this terrible disease. 
Just as extraordinary has been the global scientific 
response by biomedical researchers to develop 
therapeutics and vaccines to treat and prevent this 
disease, and ultimately control the pandemic. We 
have witnessed incredible scientific achievements, 
possibly the most remarkable of which in 2020 was 
the first phase one clinical trial of a COVID-19 vaccine 
commencing less than two months after the genetic 
sequence of SARS-CoV-2 was first published. It has 
been an incredible year for biomedical research, and 
indeed the global medicines regulatory community. 
Protection of public health is foundational to every 
aspect of our work, and I am extremely proud of the 
HPRA and the role we have played in the national 
COVID-19 response. For several years, we have 
emphasised the importance of collaboration in 
carrying out our role to ensure better outcomes for 
public and animal health protection. Throughout 
2020, the HPRA has provided expert regulatory 
support to colleagues from across multiple levels 
of government responsible for health service 
delivery, in addition to sustained engagement with 
healthcare professionals and patients. Because of 
our engagement and partnership with colleagues 
from across the broader national health care system, 
I believe there is now a greater understanding 
and appreciation of the HPRA’s role as it relates 
to medicines, medical devices and other health 
products in protecting and enhancing public health.  
In addition to our role in the national COVID-19 
pandemic response, the HPRA has also contributed 
to a range of activities at European level, not least 
of all through the provision of strategic direction and 
leadership within the European Medicines Regulatory 
Network (EMRN). Moreover, representatives from 
across the organisation have expertly contributed to 
various pandemic preparedness activities through 
European Medicines Agency (EMA) scientific 
committees, task forces and working groups, in 
addition to our involvement in EMA scientific 
assessment of COVID-19 therapeutics and vaccines. 
We have also worked steadfastly with other health 
stakeholders throughout the year at both national 
and European level to support the availability 
of critical medical devices such as ventilators, 




The impacts of COVID-19 will remain with us for some 
time and as part of this, we will continue to closely 
monitor the safety of vaccines to ensure the benefits of 
vaccination continue to outweigh any risks. Following 
the introduction of an extraordinary suite of adapted 
regulatory procedures, the HPRA and the broader 
global regulatory community are committed to a 
period of reflection to consider the learnings from this. 
What is interesting is that as regulators we are not just 
considering the success of these adapted regulatory 
procedures on a national or even European basis, but 
on a global level through the work of the International 
Coalition of Medicines Regulatory Authorities (ICMRA). 
There is a real opportunity not only for more agile 
value-add regulatory approaches, but also greater 
harmonisation and convergence across global regions. 
Positioning patient safety and wellbeing at the heart 
of all decision-making will ultimately facilitate robust, 
effective and sustainable regulation. 
Success of the Shortages 
Framework
Over the last number of years, we have invested 
resources to develop a framework to ensure enhanced 
management of medicines shortages nationally. This 
work is progressed through close cooperation with the 
Department of Health and the HSE in addition to our 
engagement with a range of stakeholders, including 
manufacturers, marketing authorisation holders, 
wholesale distributors, healthcare professionals, 
patients and representative groups. The return on 
investment and success of the framework has been 
clear, particularly in the context of both Brexit and 
COVID-19. Through our engagement with key 
stakeholders, Ireland has been able to manage 
the supply of critical medicines to meet healthcare 
demands and avoid any shortage of critical medicines 
despite the significant difficulties presented by Brexit 
and COVID-19, respectively. 
Brexit
The work of our internal cross-departmental task force, 
which was established to inform HPRA Brexit planning, 
continued throughout 2020. This was in addition 
to considerable engagement with key stakeholders 
including the Department of Health, the HSE, the 
European Commission, European National Competent 
Authorities (NCAs), marketing authorisation holders 
and distributors. As a result of the tireless efforts 
of all involved, the potential risk to the supply of 
critical medicines and medical devices was essentially 
avoided. Apart from a very small number of cases, 
for which alternatives were available, supply was 
preserved. That said, the long-term risk posed by 
Brexit may only become apparent in the coming years. 
As a result, we will continue to monitor the situation 
closely and engage with key stakeholders to ensure 
the supply of medicines and medical devices.  
Looking Ahead to 2021 and Beyond
We have seen how an integrated public health system 
can achieve incredible progress to protect public 
health in response to one of the most devastating 
global pandemics in over a century, in addition to 
mitigating the very significant potential disruption to 
the supply of medicines resulting from Brexit. Now 
more than ever, stakeholders from across the health 
system, in addition to the biopharma and medtech 
industries, must continue to work collaboratively, 
to ensure continued access to safe and effective 
medicines, medical devices and other health products. 
As we embark on the implementation of the next 
iteration of the HPRA’s new strategic plan, I am excited 
to build and sustain new and existing partnerships 
with colleagues from across the national public health 
system, in addition to maintaining positive working 
relations with researchers to support innovation. We 
have set ambitious goals and objectives, and from a 
personal perspective, I have truly enjoyed working 
with our Authority in shaping the next stages of the 
HPRA’s development. Thanks to their vision and 
strategic oversight, I believe the HPRA will continue 
to excel in health product regulation through science, 
collaboration and innovation. 
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Background
On 31 December 2019, the WHO Country 
Office in China was notified of a cluster 
of viral pneumonia cases in Wuhan, the 
capital of Central China’s Hubei province. 
By late January 2020, the zoonotic SARS-
CoV-2 virus had already been identified as 
the cause of this viral pneumonia, with the 
respiratory disease becoming known as 
COVID-19. The WHO ultimately declared 
COVID-19 a pandemic on 11 March, having 
already spread to 114 countries, resulting 
in more than four thousand deaths. With 
that announcement, SARS-CoV-2 became 
the first coronavirus to cause a global 
pandemic.  
While COVID-19 has spread rapidly both 
within and between countries, the volume 
of published scientific research investigating 
almost every aspect of this disease was 
equally as rapid. By the end of 2020, there 
was approximately 100,000 COVID-19 
related scientific publications, representing 
the greatest surge in biomedical research 
on a single topic in documented history. 
Within weeks of identifying the first cases of 
viral pneumonia, clinical trials were already 
underway investigating the safety and efficacy 
of experimental vaccines to protect individuals 
against COVID-19 disease. 
HPRA Regulatory Response
In an effort to ensure the availability of safe 
and effective COVID-19 therapeutics and 
vaccines, in addition to supporting the rate at 
which biomedical research was progressing 
throughout 2020, medicines regulators, 
including the HPRA, implemented a range of 
adapted regulatory processes and procedures 
to meet healthcare demand for critical health 
products. There are many examples of the 




ensure access and availability of medicines, 
medical devices and other products to protect 
public health. Of particular note, there has 
been:
– Accelerated assessments for therapeutics 
and vaccines required in the context of the 
pandemic including the provision of rapid 
scientific advice and the implementation of 
rolling reviews and expedited assessment 
of conditional market authorisation (CMA) 
applications to safely accelerate the access 
to safe and effective products;
– The use of the exceptional change 
management processes for post-approval 
changes for medicines and vaccines 
required for the treatment and prevention 
of COVID-19;
– Greater use of technology to disseminate 
product information to healthcare 
professionals and patients; 
– Adaptation of various regulatory 
compliance requirements to take account 
of the switch in the working environment 
for manufacturing facilities, specifically, 
the transition from on-site to remote 
inspections.
To ensure continued access to critical 
medicines and medical devices, and to 
support the broader national pandemic 
response from a regulatory perspective, there 
has been a range of cross-functional activities 
and work-related agilities introduced across 
the HPRA. Significant engagement and 
collaboration with colleagues from the wider 
public health system further complemented 
these adapted regulatory procedures 
introduced to ensure the continued supply 
of critical health products. HPRA specific 
COVID-19 related activities and significant 
engagements with external health system 
partners undertaken by the HPRA include the 
following:
 
Medicines Availability and Authorisation
– Participated in COVID-19 planning with the 
Department of Health, the HSE and the 
National Immunisation Office (NIO) through 
participation in the National Public Health 
Emergency Team (NPHET).
– Worked in partnership with the Department 
of Health and the HSE to minimise and 
proactively address any risks posed to 
the ongoing supply of medicines to Irish 
patients. This work involved liaising closely 
with industry stakeholders (including 
representative bodies, manufacturers and 
wholesalers) and healthcare professionals, 
with the objective of mitigating and, where 
possible, preventing shortages so that there 
remained continued access to medicines for 
patients with COVID-19.
– Worked with the Department of Health and 
Health Research Board Clinical Research 
Coordination Ireland (HRB CRCI) to 
facilitate the establishment of the WHO 
SOLIDARITY Trial.
– Collaborated with the Department of 
Health and the Office of National Research 
Ethics Committee to support expedited 
regulatory review for COVID-19 related 
health research.
– Contributed to multiple ad hoc meetings  
of working parties and committees to 
support rolling reviews and expedited 
timelines associated with conditional 
marketing authorisation (CMA) assessments 
for COVID-19 vaccines and therapeutics.
– Co-operated with the drafting and 
development of HSE clinical anti-viral 
guidance for therapeutics used in the 
treatment of COVID-19 disease.
– Active engagement in the assessment of 
COVID-19 vaccines and therapeutics at 
the EMA’s committee for human medicines 
(CHMP) and its COVID-19 EMA pandemic 
task force (COVID-ETF).
12
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Medicines Safety Monitoring
– Published regular COVID-19 specific safety 
updates detailing the national reporting 
experience, in addition to communication of 
the latest safety information to healthcare 
professionals via dedicated Drug Safety 
Newsletters (DSN) and direct healthcare 
professional communications (DHPC).
– Provided rapid scientific assessments and 
communication of emerging safety issues to 
support HPRA colleagues at NPHET, as well 
as the HSE and Department of Health.
– Actively contributed to newly established 
COVID-19 safety monitoring activities, at 
both national and European level, including:
- Assessment of safety issues associated 
with repurposed therapeutics, 
including, for example, non-steroidal 
anti-inflammatory drugs (NSAIDs), 
angiotensin receptor blockers (ARBs), 
angiotensin converting enzyme (ACE) and 
hydroxychloroquine;
- Participation in working groups aimed 
at vaccine pharmacovigilance and safety 
monitoring preparedness;
- Significant involvement in the EMA’s 
Pharmacovigilance Risk Assessment 
Committee (PRAC). 
– Conducted accelerated assessment of the 
marketing authorisation applications for 
both therapeutics and vaccines.
– Provided regulatory support concerning 
COVID-19 vaccines to the National 
Immunisation Advisory Committee (NIAC).
Compliance
– Adopted a suite of extraordinary risk-
based flexibilities to ensure the continued 
availability of medicinal products, including: 
- Manufacturing requirements; 
- Importation of finished products and 
active ingredients;
- Variations requests;
- Changes to good practice (GxP) 
inspections, transitioning from on-site to 
fully remote or combined inspections.
– Led on the development of an EMA 
guideline on remote inspections and distant 
assessments.
– Worked together with colleagues from An 
Garda Síochána and Revenue’s Customs 
Service to proactively monitor the supply 
chain for unauthorised or falsified COVID-19 
health products. Additionally, monitored 
and responded to the advertising and 
promotion of unauthorised/non-compliant 
treatments and medical devices purported 
to be for the detection, cure or prevention 
of COVID-19.
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Medical Devices
– Worked as part of the medical devices 
criticality assessment group, a subgroup 
of NPHET to provide regulatory advice 
and input on relevant medical devices. The 
HPRA was also a member of the NPHET 
subgroup on diagnostic testing approaches.
– Developed a specific process for COVID-19 
regulatory derogations for critical non-CE 
marked devices where there is an identified 
urgent public health need.
– Worked closely with the Health Information 
and Quality Authority (HIQA) to support 
rapid health technology assessment of 
alternative diagnostic testing for SARS-
CoV-2, as well as working with the 
Health and Safety Authority (HSA), the 
Competition and Consumer Protection 
Commission (CCPC) and the National 
Standards Authority of Ireland (NSAI), in 
relation to products such as facemasks, 
gowns and gloves.
– Provided regulatory support to the 
Department of Health regarding the use of 
antigen diagnostic tests (ADTs) and rapid 
antigen diagnostic tests (RADTs).
Future Pandemic Response
Continued Regulatory Support and 
Interaction with Public Health Partners
While significant progress has been made 
in the authorisation of safe and effective 
therapeutics and vaccines in response to the 
COVID-19 pandemic, the HPRA’s regulatory 
responsibilities will continue throughout 
the coming year. Importantly, the HPRA will 
continue to provide regulatory support in 
respect of medicines and medical devices 
to, or as part of, a range of public health 
partners, including the Department of 
Health, NIO, NPHET, NIAC and the High-
Level Task Force on COVID-19 Vaccination. 
As vaccines and indeed therapeutics 
progress through their life cycle, the timely 
communication to health system partners 
of any post-authorisation changes affecting 
the optimal use of these products will be 
critically important. Of significance, the 
HPRA will also continue feeding into the 
general Government and Department of 
Health communications strategy to ensure 
alignment of key messaging from a regulatory 
perspective.
Safety Monitoring of COVID-19 
Vaccines
In addition to future assessment of new 
vaccines and therapeutic candidates, 
combined with inspection activities to 
ensure regulatory compliance of authorised 
COVID-19 related products, extensive safety 
monitoring will continue throughout 2021 to 
ensure authorised vaccines remain safe and 
effective. Following a request to healthcare 
professionals and members of the public 
to submit reports of suspected side effects 
following vaccination, there has been a 
significant increase in the number of reports 
received, which allows regulators to monitor 
vaccine safety and take the most appropriate 
action required should new or re-emerging 
safety issues arise.
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The UK left the European Union on 
31 January 2020, which commenced a 
transition period to 31 December 2020 
to allow for negotiation of the new 
relationship between the UK and EU. 
In June, the UK formally rejected any 
extension to this period and therefore 
provided a definitive timeline to prepare 
for Brexit, with or without a trade 
agreement. During the transition period, 
the UK remained subject to EU law and 
while it could not act as a lead Member 
State nor participate in the EU institutions, 
it remained within the economic union and 
subject to medicines and medical devices 
legislation.
After some months of negotiations and 
with all parties preparing for a ‘no-deal’ on 
31 December, the Trade and Cooperation 
Agreement (TCA) was signed by the EU and 
UK on 24 December. The TCA came into 
effect from 1 January 2021 alongside the 
Northern Ireland Protocol. Late December 
also saw the EU Commission agreeing to 
provide four derogations to Ireland (IE), Malta 
(MT), Cyprus (CY) and Northern Ireland (NI). 
These exemptions, of one year, were focused 
on the special characteristics of these markets 
for medicines and their greater dependency 
on the UK market. They also reflect the 
particular needs of Northern Ireland arising 
out of the NI protocol.
Planning  
for Brexit –  
Annual 
Update on  
Progress
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Year-End Emergency Planning 
After four years of planning, the end of the 
transition period would mark a fundamental 
change to the EU and Ireland’s relationship 
with the UK. With limited progress in 
negotiations, the HPRA continued its ‘no-
deal’ preparations throughout the year. 
In this context, the HPRA continued to 
provide guidance and direction to industry 
stakeholders based on a requirement for 
them to carry out all their regulatory changes 
in advance of the 31 December deadline. 
This involved confirming that their supply 
routes were capable of continuing supply to 
Ireland and reviewing stock levels to ensure 
that they had sufficient product available 
in the event of issues affecting entry points 
to Ireland as well as those in the UK and 
Europe. This planning included significant 
engagement with the Department of Health 
and, through the department, onwards to 
the ‘whole of Government’ Brexit monitoring 
team. Stringent planning was in place to cover 
all expected and unexpected events as the 
transition period came to an end. 
As with previous years, the HPRA had 
contingency planning in place covering the 
following areas:
– Regulatory compliance of medicines and 
clinical trials authorised on the Irish market;
– Supply chain management and stock levels;
– Exempt medicinal products;
– Shortages protocol;
– Development of a list of essential 
medicines;
– Communications with stakeholders;
– Medical devices with UK CE marks;
– Veterinary medicines and engagement with 
the Department of Agriculture, Food and 
the Marine;
– Engagement within the European 
regulatory network.
The Trade and Cooperation 
Agreement  
The trade and cooperation agreement 
(TCA), which was signed on Christmas Eve, 
provides for no tariffs and no quotas for 
trade originating in the UK/EU and between 
these two jurisdictions, provided there are 
equivalent standards in both jurisdictions. 
However, no tariffs/quotas does not equate 
to free trade and all imports/exports are 
subject to full customs declarations and 
border inspections. The TCA reflects one 
positive agreement in an appendix related 
to medicines whereby UK and EU GMP 
certificates will be recognised in each 
other’s territories unless a particular issue 
is identified. Both parties can also choose 
to recognise each other’s third country 
inspections. This is a positive development 
and enables a more streamlined and efficient 
approach to inspection. The TCA also allows 
for the sharing of information on regulatory 
initiatives between the UK and the EU and 
perhaps paves the way for an enhanced 
relationship in the future.
Northern Ireland Protocol  
The Protocol on Ireland/Northern Ireland 
(‘IE/NI Protocol’) has been in place since the 
end of the transition period on 31 December 
2020. The IE/NI Protocol provides that the 
EU pharmaceutical acquis applies to and in 
the United Kingdom in respect of Northern 
Ireland and thus a medicinal product placed 
on the market in Northern Ireland has to 
comply with the EU acquis for medicinal 
products. Marketing authorisation applicants 
who wish to obtain a marketing authorisation 
for the United Kingdom in respect of Northern 
Ireland have to meet the requirements of 
EU medicines law subject to the exemptions 
that were agreed for 2021. The HPRA 
has provided guidance on the practical 
application of these rules.
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Key Brexit Pillars – Activities 
carried out in 2020  
The key strategic objective across all areas of 
Brexit planning remained the protection of 
supply of medicines and medical devices to 
patients and animals. 
Building on progress achieved during 2019, 
the following details the main activities and 
work streams delivered during 2020 in respect 
of our five Brexit pillars:
1. Stakeholder Engagement and 
Communications
– There was extensive communications and 
outreach with all stakeholders. The HPRA  
contacted all marketing authorisation 
holders for human and veterinary 
medicines seeking confirmation of their 
plans for regulatory compliance, stock 
levels and supply chains pre year-end. 
– All HPRA communication platforms and 
guidance documents were updated to 
reflect the impact of the transition period 
and the Northern Ireland Protocol as 
well as all emerging information from the 
European Commission, the EMA and the 
Heads of Medicines Agencies (HMA).
2. Existing Portfolio of medicines and 
medical devices
– All medicines, medical devices and 
clinical trials, which still had an exposure 
to the UK from a regulatory perspective, 
were reviewed in detail, particularly 
during quarter three of 2020. The 
HPRA had significant engagement with 
companies, requesting them to transfer 
all regulatory functions to the EU before 
31 December. Regulatory guidance 
and support was provided to ensure 
regulatory compliance.
3. Future Work
– The HPRA continued its objective of 
increasing its contribution to the EU 
network following the departure of the 
UK. Second only to Germany in terms 
of numbers, the HPRA took on the 
role of reference member state (RMS) 
for marketing authorisation holders 
who had previously used the UK as 
RMS. As outlined elsewhere in the 
report, the HPRA continues to develop 
its contribution to the centralised 
procedures including scientific advice. 
The HPRA is also increasing its outgoing 
decentralised work. 
4. Leadership/Public Health/Advocacy
– We participated in extensive planning 
with the Department of Health, the HSE 
and the Food Safety Authority of Ireland 
(FSAI) for Brexit particularly at year-end in 
the lead up to 31 December. In addition, 
we participated in all Commission and 
other EU meetings to advocate and 
promote greater understanding of the 
potential unique impact of Brexit for 
Ireland. In particular, the HPRA engaged 
with the Commission on issues specific 
to the Irish market such as dual-labelled 
medicines and the Falsified Medicines 
Directive.
5. Internal Capability
– Throughout 2020, we devoted expert 
staff resources to this important area to 
ensure the availability of sufficient staff 
levels to manage the implications of 
Brexit.
Authorisation and Registration
• Prior to a new medicine being placed on the 
Irish market, it must be assessed and authorised 
(licensed) by the HPRA or by the EMA in 
conjunction with the European Commission. The 
assessment involves establishing that a medicine’s 
health benefits outweigh its known risks. Where 
this is the case, it may be granted a marketing 
authorisation.
 There are a number of routes through which a 
product can be authorised by the HPRA. These 
include the national procedure, the mutual 
recognition procedure (MRP) and the decentralised 
procedure (DCP). Both MRP and DCP involve 
the simultaneous submission of applications in a 
number of EU Member States. 
 The centralised route is co-ordinated by the EMA 
and results in an authorisation that is granted by the 
European Commission and is valid across Europe. 
The assessment is carried out by Member States 
appointed as lead assessor (rapporteur), joint lead 
assessor (co-rapporteur) and peer reviewer, with 
input also from all other Member States.
 During the year in review, the total number of new 
medicines authorised in Ireland was 424. The 2020 
figure incorporates: 
– 61 new national applications including 45 parallel 
import applications; 
– 39 applications made under the MRP and 147 
applications made under DCP. The HPRA acted as 
reference (lead) Member State for the assessment 
of 23 of these DCP applications;
– 12 rapporteurships and six co-rapporteurships 
under the centralised route; 
– An additional 155 medicines authorised through 
the centralised route where the HPRA was neither 
rapporteur nor co-rapporteur.
– Two traditional herbal medicinal products under 
the simplified registration scheme and two 
homeopathic medicines under the simplified/
national rules schemes.
• The EMA operates a scientific advice and protocol 
assistance procedure system to applicants on the 
appropriate tests and studies in the development 
of a medicine. This is designed to facilitate the 
development and availability of high quality, 
effective and acceptably safe medicines for the 
benefit of patients. During 2020, the HPRA acted as 
co-ordinator for 119 EMA scientific advice requests 
across a broad range of conditions.
 Our national scientific and regulatory advice 
procedure functions in a similar way and assists 
commercial and non-commercial entities making 
applications for clinical trial authorisation or 
marketing authorisations. This service complements 
advice that we provide on earlier stage product 
development through our Innovation Office. During 





The HPRA grants licences for medicines 
subject to a review of their safety, quality and 
effectiveness and continuously monitors their 
use once they become available on the Irish 
market. We also approve and monitor clinical 
trials, inspect and license manufacturing 
sites and wholesalers, and investigate 
activities associated with the illegal supply, 
manufacture or advertising of medicines.
• Participation in clinical trials can enable patients to 
benefit from new and promising therapies. During 
2020, we issued 73 new clinical trial applications, 
including seven COVID-19 related trials, three of 
which were voluntary harmonisation procedures 
with the HPRA acting as lead Member State 
responsible co-ordinating work-sharing assessments 
of multinational clinical trials. 
• Reclassification of the legal status of medicines aims 
to increase the number of medicines available to 
patients without prescription where it is safe to do 
so. Of note in 2020, a medicine for the treatment 
of erectile dysfunction was authorised for non-
prescription, pharmacy-only sale.
• The HPRA publishes and maintains a list of 
interchangeable medicines to facilitate generic 
substitution by pharmacists and to allow for 
reference pricing by the HSE. By year-end, the 
interchangeable medicines list included 102 active 
substances or combinations of active substances.
• The Medicines Shortages Framework brings 
together key players in the health sector with the 
aim of developing strategies to mitigate the effect 
of shortages in Ireland. The effectiveness of this 
multi-stakeholder approach is reflected in an 11% 
reduction in the number of shortages notified in 
2020 compared to 2019. 
 This reduction was achieved in spite of significant 
challenges to medicines’ supply and distribution 
arising from the COVID-19 pandemic. The HPRA 
worked closely with the Department of Health, 
the HSE and supply chain stakeholders to quickly 
address and resolve these issues and ensure 
continuity of treatment for patients.
 The HPRA is also taking a prominent role in 
European and international initiatives that have 
been put in place in recognition of the need to 
address medicines shortages, which continues to be 
an ongoing global concern. 
• As the use of multilingual labelling continues to be 
considered as an important means of minimising 
the impact of Brexit and supporting the availability 
of medicines in Ireland, the HPRA remains actively 
involved in progressing this initiative at the HMA 
level through its Coordination group for Mutual 
recognition and Decentralised procedures – human 
(CMDh).  
 
Significant progress was achieved in 2020, including:
– The HPRA leading a working group of member 
states supporting a pilot exercise for the 
preparation of EU reduced harmonised labelling 
text for new medicine applications being 
processed through the mutual recognition/
decentralised procedures and presented this 
topic at the Interested Parties meetings. 
– Taking a leading role in updating the ‘CMDh 
Best Practice Guide on Multilingual Packaging’ 
to ensure that information on the pilot, and 
responses to feedback from member states and 
interested parties on approaches to multilingual 
packaging, was readily available to marketing 
authorisation holders.
– Updating our ‘Guide to Labels and Leaflets of 
Human Medicines’ to ensure current advice on 
development of multilingual labelling was actively 
available to national stakeholders. 
– Continuing to actively contribute at the EMA 
QRD (Quality Review of Documents) group to 
agree labelling flexibilities for COVID-19 vaccines 
and labelling exemption requests to maintain 
availability of small volume medicines. 
• To aid continuity of supply to the market place in 
the event of a medicine shortage following Brexit, 
the HPRA has also granted 181 temporary ‘batch-
specific request’ authorisations.
• We continued to monitor the numbers of 
unauthorised products notified to us through the 
exempt medicinal product scheme. One aspect 
of our approach to reducing the risks to patients 
is to actively seek new marketing authorisation 
applications for high-volume products currently 
being imported through this scheme. Two such 
authorisations were marketed in 2020 with 
significant assistance from the HPRA.
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Safety and Quality
• Adverse reactions reporting assists the HPRA, in 
co-operation with pharmacovigilance professionals 
in Europe and further afield, to look for new types 
of reactions or changing trends in reports. Reports 
submitted to the HPRA in many instances arise from 
concerns due to an observation of an unexpected 
and/or unwanted event, in the context of use of 
a medicine. They also include known adverse 
reactions, such as those described in the product 
information.  
This year:
– 7,752 suspected adverse reaction reports were 
received associated with the use of human 
medicines, which represents a 16% decrease in 
the total number of reports received as compared 
with 2019.  
– This decrease was solely related to cases received 
from marketing authorisation holders via the 
Eudravigilance database managed by the EMA, 
and can be attributed to increased stability in the 
operation of the pharmacovigilance system in 
2019 after changes to the reporting rules across 
the EU were introduced in November 2017. 
– In relation to reports to the HPRA receives from 
healthcare professionals and members of the 
public, there was a 19% increase in the total 
number of reports received as compared with 
2019.
Authorisation and registration: Key figures 2018 2019 2020
Classification queries/reviews 93 76 88
Scientific advice 
 Lead in EMA scientific advice:







Clinical trial applications 100 88 73
Voluntary Harmonisation Procedures (multinational clinical trials) 
 Lead







New medicines applications for marketing authorisations 
 National (including new parallel imports)
 Mutual recognition and decentralised RMS
 Mutual recognition and decentralised CMS













Traditional herbal medicinal products under the simplified registration 
scheme
4 2 2
Homeopathic medicines under the simplified/national rules schemes 3 3 2
Variations to marketing authorisations (Type IA, IB, II) 10,077 14,957 12,026
Articles 45 and 46 - Variations to Update Product Information 1 0 1
Renewals of marketing authorisations 597 291 390
Transfer of marketing authorisation holder 801 1,583 202
Manufacturers 127 135 138
Manufacturers of investigational medicinal products 63 69 76
Wholesalers 358 385 379













Brokers 8 8 9
Export certificates 1,319 1,367 1,019






































– Of the adverse reaction reports received by the 
HPRA in 2020, 87.6% were reported by marketing 
authorisation holders, with a further 0.6% 
reported by sponsors, in the context of ongoing 
clinical trials. It is important to note that reports 
received by companies will have been initially 
notified to them by healthcare professionals or 
members of the public. 
– Medicines subject to additional monitoring 
accounted for 18% of the reports submitted.
– The breakdown of reports submitted directly 
by members of the public and healthcare 
professionals was as follows:







Healthcare professional - Other 4
– The medicines most frequently included in reports 
to the HPRA accounted for approximately 80% 
of the adverse reaction reports received in 2020 
(see table below). It is important to note that the 
place of a medicine on this list cannot be taken 
as an indicator of safety or risk. The number of 
reports received cannot be used as a basis for 
determining the incidence of a reaction as neither 
the total number of reactions occurring, nor the 
number of patients using a medicine, is known.  




Antineoplastic medicines, including 
immune-modulating medicines, 




Anti-infective medicines, including 




Medicines for the treatment of Diabetes 
Mellitus 261
Medicines for the treatment of Parkinson’s 
Disease 257
Other nervous system medicines 246
Cardiovascular medicines, including  
anti-hypertensive, anti-arrhythmic, and 
lipid lowering medicines
244
Analgesics, including medicines for 
prevention and treatment of migraine 208
Pituitary and hypothalamic hormones and 
analogues 199
*  Please note that in some cases treatment may have involved 
more than one medicine from the groups listed.
– Of the new adverse reaction reports received by 
the HPRA in 2020, 137 patients were reported 
to have died while on treatment. The following 
table outlines the medicines or class of medicines 
associated with the highest number of reports. In 
many of these cases, the patients concerned had 
significant underlying illness and were treated 
with multiple medicines and/or surgery, which 
may also have contributed to the outcome. In 
addition, many of these cases were influenced 
by disease progression or other complications 
unrelated to the medicine. The majority were 
associated with medicines used in the context of 
products subject to close monitoring, those used 
in the management of severe underlying medical 
conditions, in patient support programmes and 
special patient monitoring programmes.
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Antineoplastic medicines, including 
immune-modulating medicines, 




Antithrombotic medicines including  
anti-coagulant and anti-platelet medicines 8
Anti-infective medicines, including 
antibacterials, antimycotics, antivirals and 
immunoglobulins
6
Cardiovascular medicines, including  
anti-hypertensive, anti-arrhythmic, and 
lipid lowering medicines
4
Pituitary and hypothalamic hormones and 
analogues 4
Medicines for the treatment of Parkinson’s 
Disease 3
Medicines for the treatment of Epilepsy 3
Medicines used for the treatment of 
addictive disorders 3
Analgesic medicines 3
* Please note that in some cases treatment may have 
involved more than one medicine from the groups listed.
• The HPRA also plays a key role in monitoring 
the safety of medicines on the Irish market via 
our vigilance assessment and risk management 
activities. This incorporates our contribution to  
the work of the PRAC at the EMA. During 2020,  
the HPRA:
– Continued our involvement in the work-sharing 
initiative for signal detection within the EU, acting 
as lead Member State for the monitoring of 70 
nationally-authorised active substances. Serving 
as PRAC rapporteur, we were also responsible for 
the further management of any signals detected 
in relation to 56 centrally authorised medicines 
(containing 40 active substances / combination of 
active substances);  
– Participated in the EU periodic safety update 
report (PSUR) single assessment procedure 
and national assessments contributing to the 
evaluation of 691 PSURs and leading the single 
EU assessment for 38 procedures;
– Participated as a concerned Member State in six 
ongoing safety referrals, five of which reached a 
conclusion during the year;
– Contributed to the review of 408 risk 
management plans (newly approved or updated) 
submitted via national, mutual recognition, 
decentralised and centralised procedures. We 
also provided assessment input to 557 post-
authorisation safety procedures (including 
safety study protocols, reports and other post 
authorisation safety-related measures).
• The HPRA continues to engage with multi-
stakeholder groups, including patient and 
clinical practice representatives, to facilitate 
clinical readiness at national level for new 
recommendations on the safe and rational use of 
medicines following major EU benefit-risk reviews. 
• Also during 2020, the HPRA progressed a research 
project, in collaboration with researchers from 
the Royal College of Surgeons in Ireland (RCSI), 
to assess the effectiveness of risk minimisation 
measures to prevent harms from teratogenic 
medicines. The project was funded through a 
Health Research Board Applied Partnership Award, 
bringing together the HPRA as knowledge user and 
the RCSI as academic researcher.  
• The HPRA’s inspections programme focuses on 
ensuring compliance with relevant standards and 
legislation. This year, there were: 
– 63 good manufacturing practice (GMP) 
inspections at sites that produce human 
medicines or active substances;
– 40 good distribution practice (GDP) inspections at 
wholesalers and distributors;
– Six  good clinical practice inspections at 
investigator or sponsor sites;
– Five pharmacovigilance inspections;
– One regulatory compliance inspection conducted 
at the premises of a marketing authorisation 
holder to determine the level of compliance with 
the legal requirements for the marketing and 
advertising of medicines. 
• The risk-based sampling and analysis programme is 
part of our monitoring of the quality and safety of 
medicines on the Irish market and those which are 
manufactured in Ireland for export. It involves the 
analytical testing of products and the examination 
of their packaging and labelling. In 2020, 433 
cases were opened under the programme. These 
included:
– Examination of the packaging and labelling of 
224 medicines. Fifty-eight non-compliances were 
identified. These included the absence of safety-
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related information in package leaflets and summary 
of product characteristics (SmPCs), a number of 
braille-related issues on outer cartons, and other 
packaging and labelling issues. In addition, a 
number of non-compliances with the Falsified 
Medicines Directive were identified.  Appropriate 
follow-up actions were taken in each case.
– Analytical testing of 205 medicines and other 
samples of products. With respect to non-
enforcement samples, the majority were found to 
be compliant with their specifications. However, 
a number of out-of-specification results were 
obtained. While the most frequent of these were 
appearance or reconstitution related, tablet 
disintegration and tablet subdivision out-of-
specification results were also obtained. Appropriate 
follow-up actions were taken in each case, including 
the recall of a batch of an unauthorised medicine 
used to treat COVID-19 patients.
– Usability checks on four medicines were performed, 
in response to earlier quality defects reports having 
been received on those medicines. Three of the 
samples were found to be non-compliant and 
appropriate follow-up actions were taken.
• The quality defect and recall programme 
investigates, on a risk basis, reports of suspected 
quality defects in medicines and in their related 
active substances. It also co-ordinates recalls from 
the Irish market. Quality defects pertaining to 1,408 
medicines for human use were reported or identified 
in 2020. This represented a 49% increase over the 
2019 figure (948). The risk classifications assigned, 
along with the corresponding figures for the previous 
years, are outlined in the following table:          
Classification 2018 2019 2020
Critical quality defects 325 259 312
Major quality defects 280 291 701
Minor quality defects 308 375 378
Number of reports not justified 12 23 17
Total Number Quality Defects 925 948 1,408
 The majority of reports (40%) were submitted 
by pharmaceutical companies, including 
manufacturers, distributors and/or marketing 
authorisation holders, and other competent 
authorities (37%). Significantly, in 2020, an 
increased number of reports were also submitted by 
community pharmacists (20% of the total) through 
the HPRA online reporting portal.
• In certain cases, it is necessary to withdraw, or 
recall, medicines from the Irish market in order to 
protect public health. During the year, 72 human 
medicines were recalled, for reasons outlined in the 
table below. This was a significant decrease over 
2019, when 125 medicines were recalled.  However, 
in many cases in 2020, Caution in Use Notifications 
(CIUNs) and Dear Healthcare Professional 
Communications (DHPCs) were issued for medicines 
with a quality defect, where a recall action was not 
initiated or where an out-of-stock situation for a 
medicine might arise as a result of a quality defect 
issue. Fifty-two such communications occurred 
during 2020.
Cause of Recall Number of 
Products
Non-compliance with specifications 18
Lack of Sterility Assurance issues 10
Marketing Authorisation Non-compliance 
issues 8
Non-compliances with GMP 7
Erroneous distribution issues 5
Cold chain/temperature excursions 4
Contamination issues 4
Other causes 16
• The HPRA monitors the sale of certain consumer 
health products in outlets such as grocery 
shops, health food shops and, where necessary, 
pharmacies. During 2020, 22 cases were 
investigated, some of which involved multiple 
products. Of these:
– Twenty one cases related to the sale of medicines 
that did not carry a valid registration number 
or authorisation number for the Irish market, 
resulting in 32 medicines being removed from 
sale and necessary follow-up actions being taken;
– One case related to an investigation into a non-
compliance with the paracetamol regulations 
as established by the Medicinal Products 
(Prescription and Control of Supply) Regulations 
2003. 
 In addition, 66 queries linked to the sale of health 
products in Ireland were addressed.
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• Under our enforcement programme:
– The HPRA detained 1,610,295 dosage units 
(including tablets, capsules and vials) of falsified 
and other illegal medicines in 2020, compared 
to 1,018,678 dosage units in 2019. The products 
detained included sedatives (36%), erectile 
dysfunction medicines (30%), analgesics (9%) and 
anabolic steroids (6%). 8,043 enforcement cases 
were initiated, compared to 6,167 in the previous 
year;
– Several HPRA operations took place in 
conjunction with An Garda Síochána and 
Revenue’s Customs Service. These operations 
resulted in several large detentions, including, in 
one case, the detention of over 370,000 erectile 
dysfunction tablets;
– We initiated three prosecution cases and issued 
eleven voluntary formal cautions. Prosecutions 
are taken where the HPRA considers that there 
is a significant risk to public health or where 
there are persistent non-compliances. All 
three prosecutions related to the unauthorised 
supply of anabolic steroids. We also supported 
prosecutions brought by the Director of Public 
Prosecutions in relation to the illegal supply of 
medicines;
– The Interpol-coordinated Operation Pangea XIII 
was a year round operation designed to enhance 
worldwide cooperation between health products 
regulators and other government agencies. The 
continued joint agency cooperation between the 
HPRA, Revenue’s Customs Service and An Garda 
Síochána was reflected in the HPRA detention 
figures for 2020. 
– In addition, the monitoring of websites, online 
marketplace advertisements and social media 
sites throughout the year resulted in the 
amendment or shutdown of 482 websites, 
e-commerce listings and/or social media pages.  
Legislation and Regulation
• The implementation of new Clinical Trial Legislation, 
Regulation EU No 536/2014, is provisionally planned 
for 2022, subject to the development of the Clinical 
Trial Information System (CTIS) by the EMA. 
 The following national activities were progressed 
during 2020 to support clinical research:
– We continued to engage with the Department of 
Health and the National Office for Research Ethics 
regarding the implementation of the Regulation 
and the development of national legislation; 
– We continued to offer a pilot project for 
simultaneous submission of applications to both 
the HPRA and ethics committee, which enables 
preparation for implementation of the Regulation. 
Guidance and templates for sponsors are 
available on our website;
– We actively participated in the European 
voluntary harmonisation project, which is similar 
to the approval process for clinical trials under the 
planned new legislation.
• Since 9 February 2019, under the Falsified Medicines 
Directive, the outer packs of prescription medicines 
must carry safety features in the form of an anti-
tamper device and a barcode containing unique 
identifiers, including a serial number to allow 
verification of the authenticity of the packs. In 2020:
– Work on the national implementation and 
introduction of these measures intensified. We 
worked with the Irish Medicines Verification 
Organisation (IMVO), which was responsible for 
establishing and managing the repository and 
software systems; 
– We contributed to a national oversight steering 
group of stakeholders which met regularly 
to monitor progress on implementation both 
nationally and across the EU;
– We contributed to the EU Expert Group on Safety 
Features and led one of its working groups to 
develop guidance on supervision of the national 
repositories of unique identifiers;
– Notwithstanding these efforts, the drive for full 
implementation was considerably hampered 
by the COVID-19 pandemic and the process 
remained in a ‘use and learn’ phase at year-end.
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Stakeholders and Partners
• There has been significant engagement with 
a range of partners from across multiple levels 
of government, including key public health 
stakeholders responsible for health care delivery in 
response to Brexit and the COVID-19 pandemic. 
Please refer to dedicated earlier sections of this 
report for further detail. 
• As in recent years, the HPRA delivered a 
programme of presentations and talks at 
external stakeholder events such as meetings, 
seminars, conferences and training courses. 
Such presentations provide stakeholders, 
including healthcare professionals and regulatory 
professionals, with access to relevant, up-to-date 
regulatory and safety information. In addition, 
a programme of presentations was delivered to 
undergraduate and postgraduate students studying 
courses related to the role of the HPRA. A full list of 
all presentations delivered during 2020 relevant to 
human medicines is provided in Appendix 2. As a 
result of the public health measures introduced in 
response to the COVID-19 pandemic, presentations 
were delivered remotely from March onwards.
• Publications and Information 
– The Drug Safety Newsletter provides important 
safety information to healthcare professionals 
with hyperlinks to product information and other 
relevant documents on the HPRA and EMA 
websites. Five issues of the newsletter were 
published and distributed to registered healthcare 
professionals, all of which are accessible from 
the HPRA website. A full index of topics covered 
during the past year is included in Appendix 3.
– Risk communications: 
 During 2020, 113 new or updated educational 
materials were approved by the HPRA in 
addition to 22 direct healthcare professional 
communications. 
 The PRAC monthly agendas, minutes, meeting 
highlights, notifications of safety reviews 
and signals were also made available via our 
website.
– There were 21 articles provided for inclusion in 
the monthly MIMS (Ireland) publication in addition 
to two articles for the Irish Medicines Formulary. 
The full list of topics covered in these articles is 
included in Appendix 3. 
– The Medicinal Products Newsletter provides 
regulatory news and updates for those working 
in the pharmaceutical industry. Three editions 
were published on our website in 2020 and are 
available to download from the ‘Publications’ 
section. 
– HPRA guidance documents provide stakeholders, 
primarily from the industry sectors we regulate, 
with advice and direction in respect of legislation 
and regulatory requirements. A number of 
existing guidance documents were updated 
during 2020 and are available to download 
from our website. This includes a number of 
documents which were the subject of significant 
revision, including:
 Brexit guidance - human and veterinary 
medicines;
 Guide to biosimilars for healthcare 
professionals;
 Guide to new applications and variations to 
manufacturer’s authorisations.
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Authorisation and Registration
• The HPRA is focused on ensuring effective and 
consistent designation and oversight of notified 
bodies at national and European level. In 2020, we:
– Designated a notified body in Ireland under the 
new EU Medical Device Regulation (MDR);
– Continued our schedule of oversight of the 
notified body in Ireland based on ongoing 
assessment, surveillance and observed audits;
– Continued to support development of EU 
coordination of notified body designation and 
oversight through participation in the EU Notified 
Body Operations Group (NBOG) and the Medical 
Device Coordination Group (MDCG);
– Worked along with the European Commission 
and the Competent Authorities for Medical 
Devices (CAMD) on initiatives to gather data on 
notified body capacity and certification workload 
associated with MDR. 
• Supporting innovation and research of new 
technologies is a key strategic priority for the HPRA 
medical devices team. In 2020, this involved:
– The review of applications to conduct clinical 
investigations of medical devices in Ireland. The 
number of clinical investigations increased with 
nine new applications and six amendments to 
ongoing investigations. The HPRA anticipates that 
these numbers will increase further when the new 
EU Regulations are implemented; 
– A continued focus on ensuring regulatory 
requirements and processes are clear and 
accessible to potential applicants. As part of 
our commitment to encourage engagement 
during product development and innovation of 
medical technologies, we met with 11 groups 
of innovators to discuss potential clinical 
investigation applications in 2020;
– The provision of technical, clinical and regulatory 
support to the work of the HPRA Innovation 
Office on medical devices queries received.
• Manufacturers of certain medical devices and in-
vitro diagnostics (IVDs) are required to register with 
the HPRA. In 2020, the HPRA registered 183 new 
medical device economic operators (for example 
manufacturers, authorised representatives) in 
Ireland. A total of 20,757 medical devices were also 
registered. This represented a significant increase 
in registrations when compared to previous years, 
some of which is attributable to the UK’s exit from 
the European Union. During 2020, the HPRA 
estimates that 52 of the 183 economic operators 






As the national competent authority for 
medical devices, the HPRA carries out a 
range of registration, surveillance, monitoring 
and compliance activities. Our aim is to 
ensure that these health products perform as 
intended and do not compromise the health 
and safety of the patient or the person  
using them.
Safety and Quality
• We continue to develop and reinforce our market 
surveillance activities, with particular emphasis on 
proactive rather than reactive actions. Of note in 
2020:
– We further developed our lifecycle market 
surveillance strategy and planning mechanism 
to allow for more effective management and 
reporting of these activities; 
– We concluded work in leading the EU Joint 
Action on Market Surveillance (JAMS) of a 
medical devices initiative, funded by the 
European Health Programme, which aims to 
develop market surveillance activities at European 
level. The work programme was completed 
over a three-year plan and was presented at a 
European stakeholder conference attended by 
15 organisations representing patients, clinicians 
and other stakeholders, along with 23 national 
competent authorities and the EU Commission; 
– A total of 18 COEN notices were sent by HPRA to 
the European network relating to medical device 
compliance concerns;
– There were 1,120 market surveillance cases 
undertaken in 2020, a decrease compared to 
2019 due to a significant reduction in the number 
of certificate notifications from notified bodies. 
The number of complex assessment and proactive 
market surveillance activities substantially 
increased overall in 2020; 
– Significant market surveillance activities were 
undertaken in the area of medical devices 
and IVDs used in response to the COVID-19 
pandemic. This included work related to 
thermometers, ventilators, surgical/medical 
facemasks and surgical gowns in addition to 
IVDs utilising PCR (polymerase chain reaction), 
antibody and antigen based diagnostic 
technologies;   
– A number of information notices were published 
in relation to IVDs such as falsified tests for 
COVID-19. Information notices were also 
published to provide advice to the public about 
devices such as thermometers and COVID tests;
– An information notice was also published on 
cybersecurity vulnerabilities for certain medical 
devices;   
– We conducted reviews of IVD devices for 
































• We continued to focus our vigilance activities 
during 2020 on the areas of user reporting and 
dissemination of HPRA medical device safety 
communications. This included:
– The receipt and assessment of 1,668 medical 
device vigilance cases, a decrease compared 
to 2019. Of the reports received in 2020, 
manufacturers accounted for 76%, 17% came 
from other competent authorities and 6% were 
received from users. Of the 956 incident reports 
notified directly to the HPRA, 11% came from 
users of medical devices; 
– There were 301 field safety corrective actions 
(FSCA) associated with the national market 
including 77 product removals conducted in 
Ireland during 2020; 
– We issued 106 national competent authority 
reports, four notified body forms and one 
vigilance enquiry form;
– We also issued 14 safety notices in relation to 
medical device issues and 17 direct to healthcare 
professional communications; 
– Implants, infusion devices, surgical devices and 
orthopaedic devices accounted for 56% of the 
total vigilance reports. Reports continue to be 
received relating to in-vitro diagnostic devices in 
the area of clinical biochemistry (10% of reports) 
and medical devices in the areas of vital signs 
monitoring (7% of reports) and respiratory devices 
(3% of reports);
– During the year, we also continued development 
work on signal detection of medical device issues.
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• As part of its market surveillance activities, the 
HPRA undertakes proactive and ‘for-cause’ audits 
of manufacturers, notified bodies and authorised 
representatives with the objective of monitoring 
compliance of devices emanating from Irish based 
organisations. During 2020, ten audits were 
performed at notified bodies, medical device 
manufacturers and authorised representative 
facilities, of which:
– One was a for cause audit;
– Nine were based on proactive market surveillance 
projects and notified body surveillance/
assessment.
Legislation and Regulation
• The Medical Device Regulation (Regulation (EU) 
2017/745) was due to become fully applicable in 
May 2020.  Due to the impact of COVID-19, and 
the unprecedented pressure on the health services 
and the medtech sector, the date of application 
of this regulation was deferred to May 2021. We 
continued our work during 2020 to help ensure 
an effective and timely implementation of these 
EU Device Regulations (EUDR) at national and 
European level. This included:
– Continued work on the HPRA programme plan for 
continued development of appropriate resources, 
processes and systems to meet our obligations 
under the new regulations;
– Engagement with key stakeholders in the 
sector to ensure awareness to the impact of the 
regulations and the development of guidance and 
communication initiatives;
– Working with the Department of Health and key 
stakeholders on national policy and national 
provisions to ensure transposition of the national 
requirements into Irish law;
– Contributing to the European Commission’s 
development of the secondary legislation 
involving implementing and delegating acts; 
28
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– Participating in the EU Medical Device 
Coordination Group (MDCG). Chaired by the 
EU Commission, this group is responsible for 
the overall coordination and governance of the 
regulatory system;
– Participating in the EU Working Groups tasked 
with developing guidance for specific functional 
areas.
• The HPRA continues to play a significant role in 
the development of EU regulatory systems and 
mechanisms to promote co-ordination,  
co-operation and consistency. In 2020, this 
included:
– Continued participation in to the Executive Group 
of the CAMD network;
– Participation in the CAMD’s Operations Working 
Group (OWG) which aims to improve co-
ordination and consistency of implementation 
of the new EU Regulations and prioritise 
implementation activities in the short, medium 
and long term;
– Continuing to lead the work of the clinical 
investigation and evaluation working group 
(CIEWG), acting as the co-chair along with the EU 
Commission.
• In early 2020, the HPRA led calls in Europe for 
a readiness check for implementation of the 
MDR, which resulted in the Commission’s Joint 
Implementation Plan agreed in March 2020. 
Throughout the year, our focus remained on 
identifying and promoting discussions on practical 
measures for implementation of the system to 
ensure the system operates effectively in practice. 
• At national level, we further developed our national 
fee-based funding model for medical devices to 
recover costs associated with our medical device 
activities. The model was revised in 2020 to 
streamline the approach and to ensure that new 
activities under the MDR are accounted for when 
MDR becomes fully applicable in May 2021. 
• We continued to participate actively in initiatives 
to promote regulatory convergence and 
harmonisation of medical devices globally through 
the International Medical Device Regulators Forum 
(IMDRF). This involved:
– Participation in the IMDRF Management 
Committee as part of the European delegation 
(along with the EU Commission, France and 
Germany); 
– Continuing to act as the IMDRF secretariat for 
the National Competent Authority Report (NCAR) 
Exchange programme; 
– Contributing to discussions and development of 
the Medical Device Single Review Programme, 
which relates to product review.
 
Stakeholders and Partners
• The advent of the COVID-19 pandemic had an 
unprecedented and significant impact on all 
stakeholders – patients, health services, industry, 
notified bodies and on government departments 
and agencies. The HPRA worked with key 
stakeholder groupings to provide guidance on the 
regulatory framework for devices and IVDs in the 
context of COVID-19. Interagency processes were 
developed to ensure CE marked critical medical 
devices were available to Irish health services 
and available to Irish patients. A specific medical 
devices COVID-19 webpage was launched and 
updated regularly with guidance and information on 
key aspects of medical device regulation linked to 
managing the treatment of patients with COVID-19. 
• In January 2020, Brexit was formalised with the 
UK departure from the EU. Our work to ensure 
preparedness for the end of the withdrawal 
agreement between the EU and the UK continued 
throughout the year. A number of stakeholder 
briefings and guidance materials were developed 
specific to the medical devices sector as well as 
participating in relevant EU taskforces on the 
certification capacity of notified bodies following 
the withdrawal of UK notified bodies.
• Our work to encourage the direct reporting of 
incidents and medical devices issues by device 
users and members of the public continued 
throughout 2020. We also continued our 
engagement with health services and healthcare 
professionals to encourage reporting and raise 
awareness of the roles and activities of the HPRA. 
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• The HPRA undertook a number of communication 
initiatives to raise awareness of the impact and 
requirements arising from the new EUDR. During 
2020, we:
– Hosted a webinar series on medical devices 
and in vitro diagnostic medical devices for 
manufacturers, authorised representatives, 
distributors and importers.  The series, which ran 
over the course of a week, had a daily average 
attendance of between 350 – 450 participants; 
– Continued to update the HPRA website and 
social media channels to provide information and 
guidance regarding EUDR;
– Provided information releases on the HPRA 
website and social media platforms relating to 
both COVID-19 and the new EU Regulations 
resulting in some of the most frequently visited 
pages during 2020.
– Delivered briefings, advice and workshops on 
the new Regulations to a range of different 
stakeholders including notified bodies and 
distributors. 
• Throughout the year, we engaged in ongoing 
strategic, operational and communication 
initiatives on a bilateral and multilateral basis 
with European and international authorities, and 
the EU Commission. We also further developed 
our bilateral partnerships with a number of 
those authorities. In addition, we participated in 
operational and strategic discussions on developing 
cooperation between the CAMD and the HMA 
networks.
• The HPRA continues to deliver a programme of 
presentations and talks to a range of external 
stakeholders. A full list of all presentations related 
to the regulation of medical devices that were 
delivered during 2020 is provided in Appendix 2.
Medical devices: Key figures 2018 2019 2020
Lead Competent Authority role 
on specific vigilance issues
74 84 106






Field safety notices uploaded 475 461 362
Medical device safety notices 39 33 14




NCARs managed as IMDRF 
NCAR secretariat
8 8 10
COEN reports (market 
surveillance and vigilance) to 
EU network
38 9 18
Medical device information 
notices
2 1 4
Market surveillance cases 
(unadjusted)
353 263 469
Notifications relating to notified 
body certificates
1,174 1,305 561




Medical device free sale 
certificates
2,581 2,710 2,520




The authorisation of blood establishments, tissue 
establishments and organ procurement organisations/  
transplantation centres permits those facilities to 
carry out specified activities. The total number of 
authorisations in place at year-end for the past five 




2016 2017 2018 2019 2020
Blood 
establishments
3 3 3 3 3
Tissue 
establishments




4 4 4 4 4
Safety and Quality
• Following collaboration with the National 
Haemovigilance Office (NHO), we submitted an 
annual report of serious adverse reactions and 
events to the EU Commission during 2020. The 
report reflected information received by the NHO 
in 2019 and included information on 55 serious 
adverse reactions and 119 serious adverse events 
that met the mandatory legislative reporting 
requirements. 
• We also submitted an annual report on serious 
adverse reactions and events associated with tissues 
and cells to the EU Commission during 2020. The 
report reflected information received in 2019 and 
consisted of some 41 reports, 33 of which met the 
legislative reporting requirements, including two 
serious adverse reactions and 31 serious adverse 
events.
• Updates to the common approach for defining 
reportable serious adverse reactions and events and 
other vigilance activities in Europe are continuing 
under the SoHO Vigilance Expert Sub-Group (VES) 
at which the HPRA is actively participating.  
• We continued to liaise with the HSE lead and 
colleagues from Organ Donation and Transplant 
Ireland (ODTI) in relation to our respective roles 
under EU and national legislation on the Quality 
and Safety of Human Organs intended for 




The HPRA is responsible for monitoring 
the safety and quality of blood and blood 
components, and of tissues and cells.  
Along with the HSE, we are joint Competent 
Authority for organs intended for 
transplantation.
– The exchange of relevant information on serious 
adverse reactions and events. In 2020, the HPRA 
received 17 reports of serious adverse reactions 
and events associated with organ donation/ 
transplantation;
– Contribution to the review of the ‘Framework 
for the Quality and Safety of Human Organs 
Intended for Transplantation’.
• We inspect relevant establishments, organisations 
and centres to monitor compliance with applicable 
national and EU legislation and guidelines on 
the quality and safety of blood, blood products, 
tissues and cells, and human organs intended for 
transplantation. Our inspection programme in 2020 
included:
– Five tissue establishment inspections, all of which 
were routine; and
– Four routine inspections of blood establishments.
– Two routine inspections at organ procurement 
organisations/transplant centres. 
Legislation and Regulation
• In relation to assisted human reproduction, we 
engaged with the Department of Health on 
development of related legislation and engaged in 
respect of the commencement of parts 2 and 3 of 
the Children and Family Relationships Act 2015. A 
related Commencement Order came into effect on 
4 May 2020. 
Stakeholders and Partners
• As the UK became a third country following Brexit, 
we published three new guides on our website in 
November to provide further information to our 
stakeholders in relation to Brexit and tissues and 
cells: 
– Brexit Guide for Stakeholders - Tissue 
Establishments;
– Brexit Guide for Stakeholders - Organisations 
Responsible for Human Application for Tissues 
and Cells - Dentists ;
– Brexit Guide for Stakeholders - Organisations 
Responsible for Human Application of Tissues and 
Cells - Hospitals.
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Authorisation and Registration
• There are a number of procedures through which a 
veterinary medicine can be authorised by the HPRA. 
These include the national procedure, the mutual 
recognition procedure (MRP) and the decentralised 
procedure (DCP). The following applications were 
issued by the HPRA during 2020: 
– Five new national applications; 
– 41 new applications made under the DCP; 
– Eleven new applications made under the MRP. 
  We acted as reference (lead) Member State for the 
assessment of three MRPs and seven of the DCPs. 
We also led a further 14 applications as RMS under 
the repeat use procedure.
 The centralised route administered by the EMA is 
another mechanism whereby veterinary medicines 
can be authorised for supply in Ireland. HPRA 
experts acted as rapporteur or co-rapporteur in 
respect of three new veterinary medicines. 
 Based on the figures presented above, the HPRA 
was the third leading national competent authority 
in the EU for outgoing work during 2020.
 Additionally, by year-end, there was a record total 
of more than 1,880 veterinary medicines authorised 
in Ireland.
• During 2020, HPRA experts acted as co-ordinator 
or joint co-ordinator for six EMA scientific advice 
procedures.
• Concerning Brexit planning and preparation, 
we focused on the HPRA’s key strategic aim of 
protecting the availability of veterinary medicines 
on the Irish market while also optimising our role 
within the European regulatory network. During the 
past year, this included:
– Continued engagement with industry to identify 
potentially vulnerable products;
– Recruitment and training of additional staff in 
response to anticipated increase in workload;
– Discussion with the UK’s Veterinary Medicines 
Directorate regarding maintenance of common 
labelling for medicines post Brexit. 
• Medicine shortages continue to be a challenge for 
many veterinary practitioners tasked with treating 
different species and conditions. Non-availability 
can arise for a number of reasons and different 
solutions are needed depending on the issues 
involved. In 2020:
– We conducted planned quarterly reviews of AR18 
and AR16 lists which provide details of veterinary 
medicines that have been granted special import 
licences by the Department of Agriculture, Food 




Our role is to grant licences for veterinary 
medicines subject to a review of their safety, 
quality and effectiveness. We continuously 
monitor the use of the products concerned 
in animals once they become available 
on the market in addition to authorising 
clinical field trials and inspecting/licensing 
manufacturing sites.
the lists to identify required medicines and 
to encourage an applicant to seek a standard 
marketing authorisation where practicable;
– Carried out gap analysis and prioritised 
applications linked to shortages;  
– Meetings were held with the Department of 
Agriculture, Food and the Marine to discuss 
shortages related issues including the need to 
develop an inter-departmental process in respect 
of potential shortages arising from Brexit; 
– Communicated and met with applicants regarding 
transfer of RMS to Ireland; 
– We worked closely with EU competent authorities 
to enable the use of common packs. 
Authorisation and registration: 
Key figures 2018 2019 2020
Classification enquiries 26 12 11
Clinical trials 10 4 5
New centralised as  
(co-)rapporteur 3 24 3
New MR/DCP as RMS 34 38 10
New MR/DCP as CMS 57 48 34
New homeopathic applications 0 3 0
New national applications 11 6 5
Renewals, national and MR 148 87 71
Variations, national and MR 1,820 2,153 789
Manufacturers of veterinary 
medicines 23 24 23
Export certificates 109 125 106
Safety and Quality
• The operation of a national pharmacovigilance 
system for veterinary medicines is dependent 
on the submission of reports by veterinarians, 
pharmacists, licensed merchants and others 
involved in dispensing or using the medicines 
concerned. These reports may be submitted either 
directly to the HPRA or to the companies marketing 
the medicines. The companies, in turn, must relay 
the data to the HPRA.
 Over the course of 2020, we received 391 national 
reports of suspected adverse events to veterinary 
medicines with the vast majority of reports, as 
in previous years, received from pharmaceutical 
companies.
2016 2017 2018 2019 2020
Adverse events 
reported 337 397 394 347 391
 
• We processed 565 periodic safety update reports 
(PSURs) which incorporated the assessment of 
individual medicines on the market in Ireland as 
well as a work-sharing initiative where we led, 
or contributed to, the assessment of a class of 
veterinary medicines for the European Union. 
• Containment of the development of antimicrobial 
resistance (AMR) is essential for public and animal 
health. Our work in this area includes the collection 
of annual information on the sale of veterinary 
antibiotics from each marketing authorisation 
holder. This information, which is included in the 
European Surveillance of Veterinary Antimicrobial 
Consumption (ESVAC), is important as it allows us 
to benchmark our usage rate against those of our 
European neighbours and to follow any developing 
trends. The data show that, due to a variety of 
factors, there are significant fluctuations in sales 
annually and, consequently, a clear trend is not 
identifiable. 
Veterinary 
antibiotic use 2015 2016 2017 2018 2019
Tonnes sold 96.9 103.4 99.7 99.4 88.8
 
• The analytical testing and examination of veterinary 
medicines is a key component of our risk-based 
sampling and analysis programme. Twelve 
veterinary medicines were sampled for surveillance 
work in 2020, one of which was included in the 
EDQM’s surveillance programme for centrally 
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authorised products. One sample was out-of-
specification when tested for average tablet weight. 
Another sample contained a package leaflet that 
was not in line with the approved leaflet text. 
Appropriate follow-up actions were taken in each 
case.
• Quality defects pertaining to 78 veterinary 
medicines were reported or identified in 2020. This 
represented a 15% increase over the 2019 figure 
(68). The risk classifications assigned, along with the 
corresponding figures for the previous two years, 
are outlined in the following table:
Year 2018 2019 2020
Critical quality defects 26 10 12
Major quality defects 43 19 36
Minor quality defects 56 38 29
Number of reports not justified 0 1 1
Total Number Quality Defects 125 68 78
 The majority of the reports (55%) were submitted 
by pharmaceutical companies, which included 
manufacturers, distributors and marketing 
authorisation holders. 44% of the reports were 
received from other competent authorities.  
• In certain cases, in order to protect animal and/or 
public health, it is deemed necessary to withdraw, 
or recall, a veterinary medicine from the Irish 
market. 
– Thirteen such recalls occurred during 2020, a 
substantial increase from the seven recalls that 
occurred in 2019.
– Three of the recalls related to stability issues, 
three to non-compliances with specifications, two 
to contamination issues and two to artwork/SmPC 
non-compliance issues.  
– Two Caution-in-Use Notifications were also issued 
for veterinary medicines to mitigate the risks 
presented by quality defect issues.
• Our inspections programme focuses on ensuring 
compliance with relevant standards and legislation. 
In 2020, there were 16 good manufacturing practice 
(GMP) inspections of sites that manufacture/test 
veterinary medicines.
Legislation and Regulation
• The new veterinary regulation came into effect on 
28 January 2019 and will be applied from 2022. 
During 2020, we continued to meet and engage 
with the Department of Agriculture, Food and the 
Marine in respect of the preparations needed to 
support the new Regulation (Regulation 2019/6). 
Planning in respect of the implications of the 
legislation on HPRA procedures is ongoing.
• We continued to monitor developments regarding 
the judicial review proceedings that contended that 
the labelling and packaging of veterinary medicines 
should be in both the Irish and English languages.  
A final judgment is awaited at time of writing. 
Stakeholders and Partners
• As part of our ongoing stakeholder engagement, in 
2020 we:
– Completed a consultation with stakeholders 
regarding the method of supply of antiparasitic 
veterinary medicinal products that are intended 
for food-producing animals, and produced a 
report on this topic;
– Met with key interested parties (veterinary and 
farming organisations) to discuss availability issues 
and possible solutions. 
• Throughout 2020, we continued our involvement 
across the EU regulatory network, which includes 
active participation at the EMA and the HMA. 
• As in recent years, we continued to deliver a 
programme of presentations to veterinarian 
students and veterinary nursing students on the 
role of the HPRA and the promotion of veterinary 
pharmacovigilance. We also presented at a 
number of industry stakeholder events. A full list 
of presentations for 2020, many of which were 
delivered remotely, is provided in Appendix 2. 
• Our Medicinal Products Newsletter provides 
updates for those working in the veterinary 
medicines sector on Irish and European legislation, 
new/revised HPRA regulatory publications and 
stakeholder events such as information days. Three 
editions were published on our website in 2020 and 
are available to download from the ‘Publications’ 
section of the HPRA website.
 We also contributed a number of articles to the 
Veterinary Ireland Journal and the It’s Your Field 
publication. Details are included in Appendix 3.
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Authorisation and Registration
• The HPRA carries out evaluations of applications 
for the authorisation of research establishments and 
projects. In addition, we assess applications from 
individuals to allow them to manage projects or to 
conduct procedures or euthanasia of animals.  
 








 As outlined in the accompanying graph, there 
was a decrease in the number of new individual 
authorisations issued in 2020 versus 2019. This was 
possibly due to the impact of COVID-19 public 







































Scientific Animal  
Protection
The HPRA is the competent authority in 
Ireland responsible for the implementation 
of EU legislation (Directive 2010/63/EU) for 
the protection of animals used for scientific 
purposes.
• In December, we published the seventh annual 
statistical report on the use of animals for scientific 
purposes in Ireland. The HPRA is required to collect 
and make publicly available, on an annual basis, 
statistical information on the use of animals in 
procedures, including information on the actual 
severity of the procedures. 
Inspections and Compliance
• During 2020, there were 17 inspections completed 
to monitor animal welfare standards and 
compliance with legislation. This total incorporated 
16 breeder, supplier, or user establishment renewal 
inspections (announced), and one compliance 
inspection (unannounced). Announced inspections 
are typically carried out as part of the authorisation 
renewal process as they allow for a comprehensive 
review of every aspect of the establishment’s 
activities and operations under the scientific animal 
protection legislation.
• Of the 29 non-compliances recorded under the 
annual inspections and compliance programme, 
38% were self-reported to the HPRA by personnel 
at the authorised establishment with the remainder 
detected on inspection or during other HPRA 
activities. Non-compliances are categorised as Type 
1, Type 2 and Type 3, with Type 1 being the most 
serious and Type 3 being more minor in nature. In 
2020, of the non-compliance reports:
– 14% were Type 1  
– 55% were Type 2 
– 31% were Type 3 
 The most common non-compliances recorded 
related to (i) breaches of project authorisations, 
(ii) breaches of individual authorisations and (iii) 
failure to comply with the requirements of Annex 
III to Directive 2010/63/EU in relation to the care 
and accommodation of animals. In relation to the 
third issue, a common example would be failure to 
maintain relative humidity in animal holding rooms 
within the required specifications.   
Legislation and Regulation
• Commission Implementing Decision 2020/569/
EU (replacing Decision 2012/707/EU) sets out a 
common format for submitting information to the 
European Commission, including non-technical (or 
lay-person) summaries of project proposals granted 
authorisation by the HPRA. During 2020, we led 
a European Commission expert working group to 
develop guidance for project applicants on drafting 
non-technical project summaries. 
Stakeholders and Partners
• We published and disseminated four ‘Regulatory 
Updates’ to provide stakeholders with the latest 
news and guidance from the HPRA including 
information on best practices in respect of the 3Rs 
and compliance with the legislation.
• We delivered a number of Laboratory Animal 
Science and Training (LAST) lectures in relation to 
the legislative and regulatory aspects of scientific 
animal protection. 
• Throughout 2020, we continued our active 
involvement in EU regulatory network, which 
includes active participation at National Contact 
Point meetings for the Implementation of Directive 
2010/63/EU. 
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Authorisation and Registration
• Import, export and holding of controlled drugs (for 
legitimate purposes) are subject to licensing. The 
Department of Health is the licensing authority 
while the HPRA handles the administrative aspects 
of the application and licensing process. Licensing 
activity consists primarily of export and import 
licences, and letters of no objection. Data for the 
past five years are outlined in the accompanying 
graph.
• The following table shows the licensing activity for 




Total 23 13 14
• We process, on behalf of the Department of Health, 
applications for licences to cultivate hemp. A 
cultivation licence is valid for a period of one year 
from the date it is granted. The below table shows 





Total 24 74 94
Safety and Quality
• We carry out inspections of manufacturers 
and distributors of controlled drugs, as well as 
some other operators, as necessary, to monitor 
compliance with the relevant requirements. In 
2020, eight inspections were conducted linked to 
the possession and/or supply of controlled drugs. 
Operators were informed of any non-compliances 



































The HPRA is responsible for reviewing the  
licence application for a controlled drug as  
listed in the schedule to the Misuse of Drugs  
Acts 1977 and 1984. Additionally, the HPRA  
regulates the movement of precursor chemicals  
used in the manufacture of licensed medicines, certain 
foodstuffs and for other scientific or laboratory uses.
Legislation and Regulation
• Throughout 2020, the HPRA provided support to 
the Department of Health in the development of 
the Medical Cannabis Access Programme. The 
HPRA continued to receive a small number of 
applications from potential suppliers seeking to 
have their products included in the programme. 
From these applications, one additional cannabis 
product was considered to meet the specified 
requirements and was added to the programme. In 
total, four cannabis products have been accepted 
for use. 
 When the programme is fully operational, 
consultants on the specialist medical register will be 
able to prescribe a cannabis-based treatment for 
patients with any of three specified conditions: 
– Spasticity associated with multiple sclerosis 
resistant to all standard therapies and 
interventions; 
- Intractable nausea and vomiting associated with 
chemotherapy, despite the use of standard anti-
emetic regimes; 
- Severe, refractory epilepsy that has failed to 
respond to standard anticonvulsant medications. 
Further information is available on the Department 
of Health website.   
Stakeholders and Partners
• In April 2020, in conjunction with the Department of 
Health, a process was initiated to issue emergency 
electronic e-licences to ensure continued 
processing of import and export licences for 
controlled substances. This e-licence can be issued 
within a short timeframe and allows for monitoring 
and tracking of the legitimate movement of 
controlled substances. Hard copy licences for 
controlled substances continued to be issued where 
possible. 
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Authorisation and Registration
• We issued 111 cosmetics free sale certificates, 
requested by companies intending to export 
products to non-European Economic Area 
countries. 
Safety and Quality
• As part of proactive market surveillance activities, 
we conducted three inspections of cosmetic 
distributors. Those distributors were informed of 
any non-compliances identified and requested 
to implement corrective actions. One Product 
Information File (PIF) review, to assess compliance 
with the Cosmetics Regulation, was also initiated. 
• Our reactive market surveillance includes 
investigation of quality-related complaints 
(compliance cases), reports of adverse events 
relating to the use of cosmetics (vigilance cases) 
and serious risk alerts received from other countries 
(Safety Gate RAPEX). 
 During 2020, 300 market surveillance cases were 
initiated, including both proactive and reactive 
surveillance of cosmetic products.
Stakeholders and Partners
• We were invited to present at the Irish Cosmetics, 
Detergent and Allied Products Association (ICDA) 
workshop ‘Regulatory Briefing with Irish Authorities 
on Brexit, Biocides, and Cosmetics Regulations’. 
Irish and UK cosmetics and detergent responsible 





The role of the HPRA is to regulate the 
manufacture, sale and supply of cosmetic 
products in Ireland. We identify and address 
cosmetic product quality and safety issues, in 
conjunction with the HSE, so that a cosmetic 
product will not compromise the health 
and safety of the consumer or the person 
applying the product. 
Inspections, Audits and Market 
Compliance
• Throughout 2020, HPRA contributions to the EU 
included participation in/leading on:  
– the drafting group for the new EU GMP Guide 
Annex 21 on importation;
– the development of a new risk assessment tool 
for the selection of medicinal products and active 
substances for surveillance testing; 
– a new risk-based tool to support inspection and 
surveillance relating to heparin manufacturers and 
their related products; 
– the development of a communication tool-kit for 
the Official Medicines Control Laboratory (OMCL) 
Network; and
– development of a procedure for remote 
assessment/distant inspection of manufacturers 
and distributors. This was in order to permit 
continued oversight of those authorisation 
holders during the COVID-19 pandemic.
Innovation Support
• The HPRA continues to focus on supporting 
innovation as one of our five strategic goals. This 
reflects our role not just to protect but also to 
enhance public and animal health. Our supports for 
innovation aim to facilitate safe and timely access 
to innovative health products and to increase and 
improve treatment options for patients. They also 
benefit the HPRA by helping to inform our future 
development and allowing us to identify novel 
product types and technologies that require new 
or adapted regulatory science approaches. Our 
actions to support innovation in 2020 included the 
following:
– The HPRA’s Innovation Office continues to 
offer regulatory support and advice to anyone 
developing an innovative health product 
or technology. Over 65% of the queries to 
Innovation Office originate from academia or 
small and medium enterprises who may have 
limited access to specialist regulatory advice. 
Medical devices was the most frequent area 
addressed through Innovation Office queries 
followed closely by medicines;
– In 2020, the HPRA was appointed as co-chair 
of the EU Innovation Network reflecting the 
prominent role that the HPRA had played within 
this group since it was formed in 2016. We also 
continued to take a lead role in the development 
of horizon scanning processes at a European 





at international level (within the International 
Coalition of Medicines Regulatory Authorities). 
Horizon scanning is intended to identify novel 
health products at an early stage and inform the 
development of appropriate regulatory tools 
and approaches. This facilitates both effective 
regulation of such products and patient access; 
- Throughout 2020, our classification process 
continued to offer advice to stakeholders on 
the borderline between different regulatory 
frameworks including medicines, medical devices, 
cosmetics and other products; 
- The HPRA is part of a consortium of European 
medicines regulatory agencies who are 
undertaking a Horizon 2020 funded project 
entitled ‘Strengthening regulatory sciences and 
supporting regulatory scientific advice’ (STARS). 
2020 was the second year of this project and one 
of the key achievements during the year was an 
EU stakeholder workshop which brought together 
representative from regulatory agencies, clinical 
research centres , funding agencies and other 
interested parties to discuss how best to facilitate 
the translation of academic medical research 
into approved health products. A number of Irish 
research centres participated in this workshop 
during which the HPRA gave a presentation on 
regulatory supports for innovation and chaired a 
break-out session. 
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STARS: Project Aims
to improve the  
direct regulatory




to strengthen  
long-term regulatory 
knowledge in general 
by reaching clinical 
scientists during 
professional training  
and qualification
to reach academic 
researchers very early  
in the planning of
relevant grant 
applications
• In our outreach activities to support innovation 
developments in Ireland:  
– The HPRA continued to meet and interact with a 
number of other state agencies and organisations 
who seek to support innovation in Ireland as well 
as representatives from third level institutions. We 
also met with individuals and organisations who 
are seeking to develop innovative health products 
and technologies to provide guidance on the 
regulatory requirements that will apply to their 
products. 
– As a result of our prominent role within the 
European network, the HPRA was invited to 
present on supports for innovation available 
from national competent authorities at the DIA 
Europe meeting, TOPRA symposium and an EMA 
event to mark the 15th anniversary of their SME 
Regulation.   
– The HPRA continues to contribute to education 
programmes at both undergraduate and 
postgraduate levels. During 2020, we developed 
and began implementing a new policy related 
to our involvement in third level educational 
programmes. We also provided training 
placements to a 4th year pharmacy student 
as part of the five-year integrated pharmacist 
training programme.
• Stakeholder communications and engagement:
– We continued our public information campaign: 
Zero Gains. The campaign is focused on building 
awareness of the many and often serious side 
effects associated with the non-medical use of 
anabolic steroids. The rollout of the 2020 media 
plan was initially impacted due to COVID-19 
but commenced in November for a period of 
approximately four weeks. The highly targeted 
campaign incorporated a mix of social media, 
website and in-app advertising in addition to 
digital audio advertising, which was included 
for the first time. This involved an audio advert 
featuring key campaign messages airing via 
podcasts and streaming music services. In respect 
of social media, the reach was extended to 
include TikTok, which has emerged as a platform 
of particular significance to our main target 
audience. The website - zerogains.ie - continued 
to be an important element of the campaign 
providing reliable and trustworthy information 
on the real risks of anabolic steroid use. Overall, 
the various channels continued to perform in line 
with expectations with strong engagement levels 
across most platforms. 
– Throughout the year, we continued our media 
communications programme to proactively 
communicate important safety messages and 
to build awareness of the role of the HPRA. We 
issued a range of press releases and website 
statements concerning safety and regulatory 




The HPRA is committed to a strategic focus 
on outreach and engagement with key 
partners and stakeholders to enhance and 
maximise the effectiveness of the regulatory 
system.
professionals and other stakeholders received 
timely and accurate information and advice. In 
addition, we responded to more than 220 initial 
and follow-up queries from national, local and 
specialist media during the year. 
– The HPRA is committed to widening its 
engagement with patients and patient 
organisations, to enable a deeper understanding 
of patient perspectives and experiences in 
relation to the regulation of health products. To 
this end, following extensive preparatory work, we 
established our first ever patient forum on a pilot 
basis with the inaugural meeting held remotely 
in September. Participants, who had responded 
to a call for expressions of interest from potential 
members in 2019, included both patients and 
representatives of patient organisations. Our 
Chief Executive and members of our senior 
management team represented the HPRA. 
A second meeting was subsequently held in 
December. Initial topics considered by the forum, 
which is independently chaired, included:
 The goals and expectations of participants;
 Development of a forum mandate, terms of 
reference and procedures;
 Initial consideration of a work programme 
including proposals around potential areas and 
topics of discussion and development;
 The HPRA’s new five year Strategic Plan 2021-
2025.
 The establishment of the forum represents 
an important and exciting new approach to 
patient-centred regulation. As an organisation, 
our primary focus is to ensure enhanced 
outcomes for patients through access to safe 
and effective health products. Consequently, 
it is imperative we listen to and work with 
patients to ensure their voice is heard and their 
perspective is incorporated into regulatory 
decision-making. While initially developed as 
a pilot, it is anticipated the forum will become 
an integral means of engaging with patients on 
key regulatory issues. Once the forum is fully 
established with an agreed mandate, procedures 
and work programme, it is intended that 
membership will be opened to other patients and 
patient groups. 
– The HPRA website – www.hpra.ie – is a key 
communications channel and we continuously 
monitor and analyse key visitor and usage 
statistics. The key findings from 2020 included: 
 More than 620,000 users of our website during 
the past twelve months; 
 There were in excess of 4.4 million page views 
in total throughout the year;
 Of those who accessed the site, more than 35% 
were mobile phone users. 
– The @TheHPRA Twitter account supports our 
communications activities and helps to direct 
additional traffic to the HPRA website. We 
continued to develop our Twitter activity during 
2020 and by year-end we had grown our number 
of followers to in excess of 3,000, an increase 
of more than 25%. Among the highlights was 
our continued participation in an international 
social media campaign to promote the reporting 
of suspected side effects from medicines. The 
#MedSafetyWeek campaign was supported 
by a range of patient organisations and other 
national health agencies. We also published a 
large volume of posts to highlight key regulatory 
messages linked to COVID-19 and Brexit. 
– Our LinkedIn account continues to support the 
growth of our employer brand. In addition, it 
facilities the dissemination of important regulatory 
and safety information to health and industry 
professionals. By end 2020, our total number of 
followers had grown to more than 12,000.
– Also during 2020, we continued to utilise our 
corporate Instagram account to highlight and 
promote certain activities and events. The use 
of Instagram stories was again a key component 
of our Zero Gains anabolic steroids information 
campaign.
• European and international contribution: 
– Details of the extensive Brexit preparatory 
work carried out by the HPRA during 2020 are 
outlined earlier in this report. As part of crisis 
preparedness in respect of Brexit, there were 
many additional meetings hosted by the EMA and 
the Commission, which included the EU Executive 
Steering Group on Shortages of Medicines 
caused by Major Events and ad hoc meetings on 
preparedness activities and shortages.
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– We continued our participation in all HMA and all 
EMA management board meetings. These were 
held virtually from March due to the COVID-19 
pandemic: 
 The coordination of the regulatory response 
to COVID-19 was a key issue for the EMA 
Management Board throughout 2020. Other 
ongoing issues considered at its quarterly 
meetings included the new veterinary 
legislation and clinical trials regulation 
implementation, including the new Clinical 
Trials Information Systems (CTIS).
 We continued our role as a member of the 
European HMA Management Group, which 
contributes to the direction and oversight of 
the HMA. In addition to attending the quarterly 
HMA meetings, we also participated as part of 
the secretariat for the monthly meetings of the 
HMA Brexit Task Force. 
– Additionally, as part of our ongoing contribution 
to the European regulatory system, HPRA 
scientific and technical staff participated in a 
broad range of committees and working parties 
at the European Commission, EMA, HMA, CAMD 
and other fora (see Appendix 4).
– The HPRA was re-elected as a member of the 
International Coalition of Medicines Regulatory 
Authorities (ICMRA) Executive Committee in 
April. Following the ICMRA Summit in September, 
the HPRA has worked alongside the FDA in 
establishing a new working group to establish a 
Pharmaceutical Quality Knowledge Management 
System. We continued to co-ordinate the 
Governance project, which involved a review 
of ICMRA’s membership structure and initiated 
a review of the terms of reference. COVID-19 
became a dominant topic for the group in 2020 
and we actively participated in ICMRA COVID-19 
Policy and Working Group teleconferences as 
well as the COVID-19 Vaccine Pharmacovigilance 
Network and the working group on remote 
inspections.
– In 2019, the EU Commission commenced its work 
in developing the new Pharmaceutical strategy for 
the EU, and the HPRA continues to participate in 
the development of that strategy.
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Key outreach and engagement figures 2020
Public consultations held:
 - Proposed regulatory fees for human products 
 - Proposed regulatory fees for veterinary medicines
 - Public consultation on HPRA Strategic Plan 2021-2025
3
Public consultations responded to:
 - Included Department of Health; Department of Business, Enterprise and Innovation; EMA; and PSI 
4
Events managed by HPRA events teams 1
Freedom of information requests 26
Requests received in accordance with the Data Protection Acts 5
Parliamentary questions 16
Queries from Government departments or members of the Oireachtas 90
Protected disclosures received by external persons under section 7(2) of the protected Disclosures Act, of 






Customer service queries 2,636
Human Resources and Change
During 2020, we continued to deliver a number of 
items under the HR and Change (HR&C) Strategy 
including: 
• Developing management and leadership capability;
• Provision of change management support;
• Progressing cross organisational group activities;
• Rollout of the Health & Wellbeing plan for 2020.
From March 2020 onwards, the focus of the HR&C 
team was redirected to provide support to all 
employees during the unplanned remote working 
environment resulting from the COVID-19 pandemic. 
As a result, for Q1 and Q2, both the HR and the 
learning and development teams were largely 
focused on operational activities and managing 
queries and issues within departments. From June 
onwards, the department progressed a number of 
key activities under each of the following strategic 
themes:
• Retention and Engagement
– Design and implementation of two staff 
surveys with the purpose of understanding 
how employees were managing while working 
remotely and identification of areas where more 
focused supports would be beneficial.
– The HPRA recognition programme completed its 
first full annual cycle, which included the KUDOS 
awards, the Accolade award and length of 
services certificates. 
– 2020 saw the continuation of our diversity 
and inclusion activities including a focus on 
educational materials and a virtual meeting with 
the external group, ‘Shout Out’. Preparatory 
activities for progression in the Investors in 
Diversity framework were initiated.
– The health and wellbeing agenda continued as a 
key focus with a number of initiatives adapted to 
the remote environment. The HPRA successfully 
achieved reaccreditation with the IBEC Keep Well 
Mark in October, which included the completion 
of a large body of preparatory work by the team 
prior to the associated audit.
• Career Development
– Outputs from the cross-organisational working 
group achieved consensus of approach from the 
Management Committee. 
– The third iteration of the graduate programme 
commenced in September 2020. Recruitment 
for the fourth iteration was also completed with 





The HPRA is committed to having the 
necessary corporate functions, systems 
and supports in place to deliver on our 
public health mission. We must ensure that 
our organisational capabilities continue to 
expand and evolve in line with regulatory and 
scientific developments and that we adapt to 
other changes in our operating environment.
• HR and Change: 
– The HR Business Partner model played a key 
role in delivering on the department specific HR 
business needs during the pandemic. 
– Coordination of COVID-19 contact tracing 
volunteers including the selection, training and 
scheduling of volunteers, and acting as main 
point of contact with the Department of Health 
and HSE. 
– HR&C held a lead role in the Business Continuity 
group and sub group, which focused on 
ensuring the health and safety of employees 
were safeguarded and relevant information and 
documents implemented. 
• Organisation Design: 
– To ensure the HPRA can respond accordingly 
to future needs, a ‘Future of Work’ project 
commenced to analyse what the impact of 
more flexible working models might be on the 
organisation.
– An operational excellence project was supported 
in its initial stage through the procurement of 
services and the provision of training.  
• Talent Management: 
– An agile recruitment process was adopted to 
support remote working and remote recruitment. 
– The recruitment and appointment of a number of 
key senior appointments was supported.  
– Consultation on the MDP (management 
development programme) was undertaken with 
directors and managers. 
– A virtualised version of our iLM-accredited train 
the trainer (TTT) programme was developed.
• Change Management: 
– Tools and supports were provided to managers to 
aid their ability to manage remotely and ensure 
any people related issues or concerns were 
managed appropriately. 
– Ongoing change management support 
was delivered to various projects across the 
organisation. This included, for example, the 
EU medical device Regulations, EOLAS and the 
rollout of Skype for Business.
IT Developments
• Enhancements continued to Eolas, the HPRA’s 
workflow and data management system, which is a 
central platform to support its regulatory activities. 
The functionality of Eolas will continue to be 
enhanced and its footprint expanded to integrate 
other HPRA processes and procedures.
• A number of significant upgrades to additional 
systems were completed during the year giving 
added capability to users in support of their 
activities.
• Upgrades were made to the office and collaboration 
infrastructure including the introduction of Skype 
for Business and enhancements to the technology 
available in meeting rooms.
• There were 562,397 regulatory submissions made 
through the Common Electronic Submission Portal 
(CESP), which is managed by the HPRA on behalf 
of the wider EU regulatory community. By year-end, 
there were 6,943 organisations availing of CESP 
with over 31,612 individual users.
Quality Management
• The HPRA’s quality management team was 
responsible for the continued implementation of 
policies and procedures relating to the General 
Data Protection Regulation (GDPR). There were five 
data subject requests received in 2020. All requests 
were managed within the required timelines.
• In the HPRA’s continued commitment to the 
quality management system, 10 internal audits 
were completed in 2020 throughout various 
departments.
• Various ‘Lean’ projects were carried out in 2020, 
supporting the culture of continuous improvement 
within the HPRA. 
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Finance
• The HPRA is committed to the highest standards of 
corporate governance. During 2020, the financial 
statements for the previous year were prepared and 
submitted for audit to the Comptroller and Auditor 
General and subsequently published in the HPRA’s 
2019 Annual Report. All financial transactions 
during the period were reflected and reported upon 
in these statements. 
• The annual review of regulatory fees for 2021, 
incorporating a public consultation, was completed 
followed by the publication of the updated fees. 
• Two internal audit reviews took place and reports 
were issued on payroll, travel and subsistence, and 
on human resources. 
Energy Usage
• The HPRA, as a public sector body, is required to 
report annually on its energy usage and actions 
taken to reduce consumption in accordance with 
the European Union (Energy Efficiency) Regulations 
2014 (S.I. No. 426 of 2014). As an organisation, 
we use electricity for lighting, air conditioning or 
heating as required and the provision of hot water. 
Natural gas is used for central heating. In 2020, the 
HPRA consumed 589.5 MWh of energy consisting 
of: 
– 339.7 MWh of electricity;
– 249.8 MWh of fossil fuels;
– 0 MWh of renewable fuels.
 Total energy reduction at year-end was 44.9%*, 
exceeding the goal of 33% by 2020 as calculated 
and published by the Sustainable Energy Authority 
of Ireland (SEAI). 
 * published by the SEAI 
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• The Authority of the HPRA met seven times in 
2020 and considered a number of strategic matters 
including the response to COVID-19, preparations 
for Brexit, strategic planning and financial matters. 
The latter included monthly management accounts, 
annual budgets and the financial statements for 
2019. The Authority also reviewed update reports 
from the Statutory Advisory Committees and the 
Audit and Risk Committee. In addition, it reviewed 
the licences for all medicinal healthcare products as 
approved by the Management Committee.
 The number of meetings attended by each 
Authority member during 2020 was as follows:
– The Audit and Risk Committee, a subcommittee 
to the Authority, met four times in 2020. Further 
details are provided in the HPRA’s Financial 
Statements. 
– The Advisory Committee for Human Medicines 
met on two occasions in 2020. The Clinical 
Trials Sub-Committee is a sub-committee to the 
Advisory Committee for Human Medicines and it 
met twelve times in the past year.
– The Advisory Committee for Veterinary Medicines 
met once.





Authority Member Number of meetings held during the 
period the member was on the Authority
Number of meetings attended during the 
period the member was on the Authority
Ms. Ann Horan 
(Chairperson)
7 7
Dr. Joe Collins 2 2
Mr. David Holohan 7 7
Mr. Brian Jones 7 5
Prof. Elizabeth Keane 7 7
Prof. David Kerins 7 7
Prof. Caitriona O’Driscoll 7 7
Dr. Diarmuid Quinlan 7 6
Prof. Richard Reilly 7 7
The Authority (Board) of the HPRA is appointed 
by the Minister for Health in accordance with 
the powers conferred by subsection 2 of 
section 7 of the Irish Medicines Board Act, 
1995. In addition to the Authority, there are 
three advisory committees. The Advisory 
Committee for Human Medicines, the Advisory 
Committee for Medical Devices and the 
Advisory Committee for Veterinary Medicines.
– The National Committee for the Protection of 
Animals Used for Scientific Purposes, a statutory 
committee to provide guidance to the regulator 
and those working in this area, met once in 2020.
• Decisions of the Authority: 
 The terms of reference of the Authority, which 
are published on the HPRA website, include 
an overview of how the Authority operates, an 
overview of all decisions taken by the Authority and 
those devolved to the Management Committee. 
 The following decisions are reserved functions of 
the Authority: 
– The Authority takes decisions relating to very 
significant and serious public and/or animal 
health matters except in circumstances where a 
meeting of the Authority cannot be convened, 
in which case the Management Committee takes 
the decision and informs the Chairperson at the 
earliest opportunity and the Authority as soon as 
is practical. 
– The Authority refuses applications, or suspends, 
revokes or terminates authorisations as set out in 
legislation except in circumstances where: 
(a) the urgency is such that a meeting of the 
Authority cannot be convened, or 
(b) the application or authorisation is subject to a 
binding European decision, or 
(c) the application or authorisation is for a clinical 
trial or clinical investigation; in which case the 
Management Committee takes the decision 
and informs the Authority. 
– Through its Audit and Risk Committee, the 
Authority approves the internal financial controls 
and the financial audit function and satisfies 
itself that the financial controls and systems of 
risk management are robust and defensible. The 
Authority appoints the internal financial auditor. 
– The Authority approves the investment policy, 
major investments, capital projects and the terms 
of major contracts. 
– Significant acquisitions and the disposal or 
retirement of assets above a threshold set by the 
Authority are subject to Authority approval. 
– The Authority approves treasury policy and risk 
management policies. The Authority approves 
corporate plans as required. 
– The Authority approves significant amendments 
to the pension benefits of the Chief Executive and 
staff
– The Authority approves the annual budget, 
monitors expenditure and supervises the 
preparation and submission of the annual 
statutory accounts. 
– The Authority makes an annual report on the 
activities of the HPRA, including a financial 
statement, to the Minister for Health. This report 
is then published. 
– The Authority selects and appoints the Chief 
Executive, with the consent of the Minister for 
Health. The terms of office and the remuneration 
of the Chief Executive are determined by the 
Minister for Health, after consultation with the 
Authority and with the consent of the Minister for 
Finance. The Authority, through its Performance 
Review Committee, conducts a process of annual 
performance appraisal of the Chief Executive. 
Succession planning for the role of Chief 
Executive is also undertaken by the Authority. 
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for the Year Ended  
31 December 2020
Governance Statement and 
Authority Member’s Report
Governance
The Health Products Regulatory Authority (the 
HPRA) was established under the terms of the Irish 
Medicines Board Act, 1995 (as amended), and is 
governed by an Authority which was appointed 
by the Minister for Health. The Authority of the 
HPRA (the Authority) consists of a chairperson 
and eight non-executive members. The Authority 
is accountable to the Minister for Health and is 
responsible for ensuring good governance, and 
performs this task by setting strategic objectives 
and targets and taking strategic decisions on 
all key business issues. The regular day-to-day 
management, control and direction of the HPRA 
are the responsibility of the Chief Executive and 
the Management Committee. The Chief Executive 
and the Management Committee must follow the 
broad strategic direction set by the Authority, and 
must ensure that all Authority members have a clear 
understanding of the key activities and decisions 
related to the HPRA, and of any significant risks 
likely to arise. The Chief Executive acts as a direct 
liaison between the Authority and management of 
the HPRA.
On 1 July 2014 the organisation changed its name 
from the Irish Medicines Board, as provided for 
in Section 36 of the Health (Pricing and Supply of 
Medical Goods) Act 2013 and SI (205/2014) Health 
(Pricing and Supply of Medical Goods) Act 2013 
(Commencement) order 2014.    
Authority Responsibilities
The work and responsibilities of the Authority are 
set out in the Irish Medicines Board Act, 1995 (as 
amended), as well as in the ‘Terms of Reference 
and Rules of Procedure’ of the HPRA, which also 
contains the matters specifically reserved for 
Authority decision. Standing items considered by 
the Authority include:
• declaration of interests,
• reports from committees,
• financial reports/management accounts,
• performance reports, and
• reserved matters.
The Authority is required by the Irish Medicines 
Board Act, 1995 to prepare financial statements for 
each financial year which give a true and fair view of 
the financial position of the HPRA and of its surplus 
or deficit for that period.
In preparing those statements the Authority is 
required to:
• select suitable accounting policies and apply them 
consistently,
• make judgements and estimates that are 
reasonable and prudent,
• prepare the financial statements on a going 
concern basis unless it is inappropriate to presume 
that the HPRA will continue in existence, and
• state whether applicable accounting standards 
have been followed, subject to any material 
departures disclosed and explained in the financial 
statements.
 
The Authority is responsible for keeping adequate 
accounting records which disclose, with reasonable 
accuracy at any time, the financial position of 
the HPRA and which enable it to ensure that 
the financial statements comply with the Irish 
Medicines Board Act, with accounting standards 
generally accepted in Ireland and with accounting 
directions issued by the Minister for Health.  The 
maintenance and integrity of the corporate and 
financial information on the HPRA’s website is the 
responsibility of the Authority.
The Authority is responsible for approving the 
annual plan and budget. It is also responsible for 
safeguarding the assets of the HPRA and hence 
for taking reasonable steps for the prevention and 
detection of fraud and other irregularities.
The Authority considers that, except for the non-
compliance with the requirements of FRS102 
in relation to retirement benefits, the financial 
statements of the HPRA give a true and fair view of 
the financial performance and the financial position 
of the HPRA at 31 December 2020.
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Audit and Risk Committee
The HPRA has an audit and risk committee 
comprising three Authority members, which met 
on 4 occasions during 2020. This committee is 
responsible for reviewing internal control matters, 
together with any other issues raised by the external 
auditors, the Authority or management. The external 
auditor is invited annually to meet with the audit 
and risk committee to brief them on the outcome of 
the external audit, and the audit and risk committee 
also meets annually with the internal auditor. During 
2020 the internal auditor carried out internal audit 
reviews on the areas of payroll, travel & subsistence 
and human resources. The audit and risk committee 
has also been involved with the review of the quality 
systems as described below.
Quality Systems
During 2020, the finance section of the HPRA 
continued the process of implementing and 
reviewing standard operating procedures (SOPs) 
under the quality management system. This process 
involved a critical review and analysis of internal 
controls and processes throughout the section 
with particular emphasis on risk management. 
This system now underpins the internal control 
environment and feeds into the internal audit 
process and ultimately into the audit and risk 
committee.
Remuneration Policy – Authority 
Members and Executive Directors
Remuneration and travel expenses paid to Authority 
members are disclosed in note 17 to the Financial 
Statements. The Chairperson receives remuneration 
as directed by the Minister for Health in accordance 
with the Irish Medicines Board Act, 1995. Other 
Authority members receive remuneration under the 
terms of the Health (Miscellaneous Provisions) Act 
2017. All Authority members are entitled to receive 
travel expenses in accordance with circulars issued 
by the Department of Health. The Chief Executive is 
remunerated in accordance with guidelines issued 
from Government and other Executive Directors are 
paid in accordance with Department of Health pay 
scales. The remuneration of the Chief Executive and 
Executive Directors are disclosed in note 18 to the 
Financial Statements.
Internal Control
The Authority is responsible for the HPRA’s systems 
of internal control. Such systems can only provide 
reasonable and not absolute assurance against 
material misstatement or loss. The systems of 
internal controls in use in the HPRA are described 
more fully in the Chairperson’s report on pages 54 
to 55.
Disclosures Required by Code of Practice 
for the Governance of State Bodies 
(2016)
The Authority is responsible for ensuring that the 
HPRA has complied with the requirements of the 
Code of Practice for the Governance of State 
Bodies, as published by the Department of Public 
Expenditure and Reform in August 2016. The 
following disclosures are required by the Code, 
and are contained in the notes to the financial 
statements:
• employee short term benefits breakdown,
• consultancy costs,
• legal costs and settlements,
• travel and subsistence expenditure, and
• hospitality expenditure.
Statement of Compliance
The Authority has adopted the Code of Practice for 
the Governance of State Bodies (2016) and has put 
procedures in place to ensure compliance with the 
Code. The HPRA was in full compliance with the 
Code of Practice for the Governance of State Bodies 
for 2020.
Performance Review
The Authority were subject to an external evaluation 
of their own performance during the year ended 31 
December 2020.
On behalf of the Authority
 
 
Date: 24 June 2021
Mr. Michael Donnelly 
Chairperson 
Mr. David Holohan 
Authority Member
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Statement on Internal Control
Scope of Responsibility
I, as Chairperson, acknowledge the Authority’s 
responsibility for ensuring that an effective system 
of internal control is maintained and operated. This 
responsibility takes account of the requirements of 
the Code of Practice for the Governance of State 
Bodies (2016).
Purpose of the System of Internal 
Control
The system of internal control is designed to 
manage risk to a tolerable level rather than to 
eliminate it. The system can therefore only provide 
reasonable and not absolute assurance that 
assets are safeguarded, transactions authorised 
and properly recorded and that material errors or 
irregularities are either prevented or detected in a 
timely way.
The system of internal control, which accords with 
guidance issued by the Department of Public 
Expenditure and Reform, has been in place in the 
HPRA for the year ended 31 December 2020 and up 
to the date of approval of the financial statements.
Capacity to Handle Risk
The HPRA has an audit and risk committee 
comprising three Authority members, which met on 
4 occasions during 2020.
The HPRA has outsourced the internal audit function 
to an independent professional firm, who conduct a 
programme of work as agreed with the audit and risk 
committee. During 2020 two internal audit reviews 
were conducted. 
The HPRA have developed a risk management 
framework, which sets out its risk appetite, the risk 
management processes in place and details the 
roles and responsibilities of staff in relation to risk. 
This framework has been made available to all 
staff, who are expected to work within the HPRA’s 
risk management policies, to alert management on 
emerging risks and control weaknesses, and assume 
responsibility for risks and controls within their own 
area of work. 
Risk and Control Framework
The HPRA has implemented a risk management 
system which identifies and reports key risks and the 
management actions being taken to address, and to 
the extent possible, to mitigate those risks.
A risk register is in place which identifies the 
key risks facing the HPRA, and these have been 
identified, evaluated and graded according to their 
significance. The register is reviewed and updated 
by management, considered by the audit and risk 
committee twice per year and presented to the 
Authority. The outcome of these assessments is used 
to plan and allocate resources to ensure risks are 
managed to an acceptable level.
The risk register details the controls and actions 
needed to mitigate risks and responsibility for 
operation of controls assigned to specific staff. I 
confirm that a control environment containing the 
following elements is in place:
• procedures for all key business processes have 
been documented,
• financial responsibilities have been assigned 
at management level with corresponding 
accountability,
• there is an appropriate budgeting system with 
an annual budget, which is kept under review by 
senior management,
• there are systems aimed at ensuring the security 
of the information and communication technology 
systems, and
• there are systems in place to safeguard the assets.
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Ongoing Monitoring and Review
Formal procedures have been established for 
monitoring control processes, and any control 
deficiencies are communicated to those responsible 
for taking corrective action, and to management and 
the Authority, where relevant, in a timely manner. 
I confirm that the following ongoing monitoring 
systems are in place:
• key risks and related controls have been identified, 
and processes have been put in place to monitor 
the operation of those key controls and report any 
identified deficiencies,
• reporting arrangements have been established 
at all levels where responsibility for financial 
management has been assigned, and
• there are regular reviews by senior management 
of periodic and annual performance and financial 
reports, which indicate performance against 
budgets.
Procurement
I confirm that the HPRA has procedures in place to 
ensure compliance with current procurement rules 
and guidelines, and that during 2020 the HPRA 
complied with those procedures.
Review of Effectiveness
I confirm that the HPRA has procedures to monitor 
the effectiveness of its risk management and control 
procedures. The HPRA’s monitoring and review of 
the effectiveness of the system of internal control is 
informed by the work of the internal and external 
auditors, the audit and risk committee which 
oversees their work, and the senior management 
within the HPRA, responsible for the development 
and maintenance of the internal control framework.
I confirm that the Authority conducted an annual 
review of the effectiveness of the internal controls 
for 2020. This review was carried out at its meeting 
on 29 April 2021. Prior to this meeting, a document 
outlining the effectiveness of the internal controls in 
the HPRA for 2020 was circulated to the Authority 
members by e-mail. This document was circulated 
on 30 March 2021.
Internal Control Issues
No weaknesses in internal control were identified 
in relation to 2020 that require disclosure in the 
financial statements.
During 2019, four supplier contracts were identified 
as not being in compliance with current procurement 
rules. A full tender process was completed during 
2020 for one of these contracts, and the other three 
contracts are expected to be tendered for in Q3/Q4 
2021.
COVID-19 Pandemic
Due to the impact of COVID-19, the HPRA carried 
out a review of its control environment, based on 
a guidance document issued by the Office of the 
Comptroller and Auditor General. Many of the 
controls in place pre-COVID continue to apply in 
the current environment. This review document was 
considered by the Audit and Risk Committee at its 
December 2020 meeting, who were happy with the 
content. 
All staff are predominately working off site, with 
many resources diverted to managing implications 
of the pandemic. This has had little or no effect on 
internal controls already in place, many of which 
were not dependant on physically being in the 
office.
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Mr. Michael Donnelly  
Chairperson to the Authority 
Date: 24 June 2021
Comptroller and Auditor General  
 
Report for presentation to the 
Houses of the Oireachtas
Qualified opinion on financial statements
I have audited the financial statements of the Health 
Products Regulatory Authority (the Authority) for the 
year ended 31 December 2020 as required under 
the provisions of section 18 of the Irish Medicines 
Board Act 1995. The financial statements have been 
prepared in accordance with Financial Reporting 
Standard (FRS) 102 – The Financial Reporting 
Standard applicable in the UK and the Republic of 
Ireland and comprise
• the statement of income and expenditure and 
retained revenue reserves
• the statement of financial position
• the statement of cash flows and
• the related notes, including a summary of 
significant accounting policies.
In my opinion, except for the non-compliance with 
the requirements of FRS 102 in relation to retirement 
benefit entitlements referred to below, the financial 
statements give a true and fair view of the assets, 
liabilities and financial position of the Authority at  
31 December 2020 and of its income and 
expenditure for 2020 in accordance with FRS 102.
Basis for qualified opinion on financial 
statements
In compliance with the directions of the Minister 
for Health, the Authority accounts for the costs of 
retirement benefit entitlements only as they become 
payable. This does not comply with FRS 102 which 
requires that the financial statements recognise the 
full cost of retirement benefit entitlements earned in 
the period and the accrued liability at the reporting 
date. The effect of the non-compliance on the 
Authority’s financial statements for 2020 has not 
been quantified.
I conducted my audit of the financial statements 
in accordance with the International Standards on 
Auditing (ISAs) as promulgated by the International 
Organisation of Supreme Audit Ins``titutions. My 
responsibilities under those standards are described 
in the appendix to this report. I am independent 
of the Authority and have fulfilled my other ethical 
responsibilities in accordance with the standards.
I believe that the audit evidence I have obtained is 
sufficient and appropriate to provide a basis for my 
opinion.
Report on information other than the 
financial statements, and on other 
matters 
The Authority has presented certain other 
information together with the financial statements. 
This comprises the annual report, the governance 
statement and Authority members’ report and the 
statement on internal control. My responsibilities to 
report in relation to such information, and on certain 
other matters upon which I report by exception, are 
described in the appendix to this report.
I have nothing to report in that regard.
Andrew Harkness 
For and on behalf of the Comptroller  
and Auditor General 
29 June 2021 
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Appendix to the report 
Responsibilities of Authority Members
As detailed in the governance statement and 
Authority members’ report, the Authority members 
are responsible for
• the preparation of financial statements in the form 
prescribed under section 18 of the Irish Medicines 
Board Act 1995
• ensuring that the financial statements give a true 
and fair view in accordance with FRS 102
• ensuring the regularity of transactions
• assessing whether the use of the going concern 
basis of accounting is appropriate, and
• such internal control as they determine 
is necessary to enable the preparation of 
financial statements that are free from material 
misstatement, whether due to fraud or error.
Responsibilities of the Comptroller and 
Auditor General
I am required under section 18 of the Irish Medicines 
Board Act 1995 to audit the financial statements of 
the Authority and to report thereon to the Houses of 
the Oireachtas.
My objective in carrying out the audit is to obtain 
reasonable assurance about whether the financial 
statements as a whole are free from material 
misstatement due to fraud or error. Reasonable 
assurance is a high level of assurance, but is not a 
guarantee that an audit conducted in accordance 
with the ISAs will always detect a material 
misstatement when it exists. Misstatements can 
arise from fraud or error and are considered material 
if, individually or in the aggregate, they could 
reasonably be expected to influence the economic 
decisions of users taken on the basis of these 
financial statements.
As part of an audit in accordance with the ISAs, 
I exercise professional judgment and maintain 
professional scepticism throughout the audit. In 
doing so,
• I identify and assess the risks of material 
misstatement of the financial statements whether 
due to fraud or error; design and perform audit 
procedures responsive to those risks; and obtain 
audit evidence that is sufficient and appropriate 
to provide a basis for my opinion. The risk of not 
detecting a material misstatement resulting from 
fraud is higher than for one resulting from error, 
as fraud may involve collusion, forgery, intentional 
omissions, misrepresentations, or the override of 
internal control.
• I obtain an understanding of internal control 
relevant to the audit in order to design 
audit procedures that are appropriate in the 
circumstances, but not for the purpose of 
expressing an opinion on the effectiveness of the 
internal controls.
• I evaluate the appropriateness of accounting 
policies used and the reasonableness of 
accounting estimates and related disclosures.
• I conclude on the appropriateness of the use of 
the going concern basis of accounting and, based 
on the audit evidence obtained, on whether a 
material uncertainty exists related to events or 
conditions that may cast significant doubt on the 
Authority’s ability to continue as a going concern. 
If I conclude that a material uncertainty exists, I 
am required to draw attention in my report to the 
related disclosures in the financial statements or, 
if such disclosures are inadequate, to modify my 
opinion. My conclusions are based on the audit 
evidence obtained up to the date of my report. 
However, future events or conditions may cause 
the Authority to cease to continue as a going 
concern.
• I evaluate the overall presentation, structure and 
content of the financial statements, including the 
disclosures, and whether the financial statements 
represent the underlying transactions and events 
in a manner that achieves fair presentation.
I communicate with those charged with governance 
regarding, among other matters, the planned scope 
and timing of the audit and significant audit findings, 
including any significant deficiencies in internal 
control that I identify during my audit.
Information other than the financial 
statements
My opinion on the financial statements does not 
cover the other information presented with those 
statements, and I do not express any form of 
assurance conclusion thereon.
In connection with my audit of the financial 
statements, I am required under the ISAs to read 
the other information presented and, in doing so, 
consider whether the other information is materially 
inconsistent with the financial statements or with 
knowledge obtained during the audit, or if it 
otherwise appears to be materially misstated. If, 
based on the work I have performed, I conclude 
that there is a material misstatement of this other 
information, I am required to report that fact.
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Reporting on other matters
My audit is conducted by reference to the special 
considerations which attach to State bodies in 
relation to their management and operation. I report 
if I identify material matters relating to the manner in 
which public business has been conducted.
I seek to obtain evidence about the regularity of 
financial transactions in the course of audit. I report 
if I identify any material instance where public 
money has not been applied for the purposes 
intended or where transactions did not conform to 
the authorities governing them.
I also report by exception if, in my opinion,
• I have not received all the information and 
explanations I required for my audit, or
• the accounting records were not sufficient to 
permit the financial statements to be readily and 
properly audited, or
• the financial  statements are not in agreement  
with the accounting records.
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 Note  2020  2019
  € €
Fee Income  3     29,712,923      27,932,876
Department of Health Funding 3    4,975,000    4,964,255 
Other Income  4              803,196      805,824 
   
         35,491,119     33,702,955  
Salaries and Wages  5     25,436,125      23,862,438 
Other Operating Costs  6           5,059,018      7,639,373 
Depreciation  2           1,080,820      1,274,848 
   
         31,575,963     32,776,659 
 
Surplus for the year before write back of Superannuation contributions   3,915,156  926,296 
Staff Superannuation Contributions  637,287  691,855
Surplus for the year          4,552,443      1,618,151
Balance brought forward  31,106,264 29,488,113




The Statement of Income and Expenditure and Retained Revenue Reserves includes all gains and losses recognised in the 
year. The Statement of Cash Flows and the notes on pages 62 to 72 form part of the financial statements.
Statement of Income and Expenditure and Retained Revenue Reserves
For the year ended 31 December 2020
Mr. Michael Donnelly 
Chairperson
Date: 24 June 2021
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 Note  2020  2019
  € €
Fixed Assets  
Property, Plant and Equipment  2        24,665,841        24,896,454  
 
Current Assets
Debtors and Prepayments 7     2,846,261       2,514,984  
Inventory of Stationery     4,936        5,533  
Cash and Cash Equivalents 9      22,629,442          2,290,820  
Short Term Deposits 10    -         17,658,240   
        25,480,639        22,469,577  
Current Liabilities - Amounts falling
due within one year
Creditors and Accruals  8     13,814,425            12,293,087  
Mortgage  13             168,337        793,332  
   
        13,982,762        13,086,419  
 
Net Current Assets          11,497,877              9,383,158  
 
Long Term Liabilities - Amounts falling 
due after more than one year
Mortgage  13     505,011              3,173,348  
 
 




Retained Revenue Reserves  12     21,053,422          19,138,266 
Superannuation Reserve  12     14,605,285          11,967,998   
    





Statement of Financial Position
As at 31 December 2020
The Statement of Cash Flows and the notes on pages 62 to 72 form part of the financial statements.
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Mr. Michael Donnelly 
Chairperson
Date: 24 June 2021
On behalf of the Authority
Mr. David Holohan
Authority Member
 Note  2020  2019
  € €
Cash flows from Operating Activities
 
Surplus for financial year   4,552,443  1,618,151
Depreciation of property, plant and equipment  1,080,820  1,274,848
(Profit)/Loss on Disposal of property, plant and equipment  0  (49)
(Increase) in Debtors  (331,277) (316,644)
(Increase)/Decrease in Stock  597 (2,035)
Increase in Creditors - amounts  
falling due within one year  1,521,338 1,532,175
Deposit Interest   (5,508)  (16,737)
Bank Interest  349,040 174,075
Cash from Operations  7,167,453  4,263,784
Bank Interest Paid   (349,040) (174,075)
Net Cash generated from Operating Activities  6,818,413 4,089,709
Cash flows from Investing Activities  
Deposit Interest Received  5,508 16,737
(Increase)/Decrease in Bank Deposits   17,658,240 (9,441,426)
Payments to acquire property, plant and equipment   (850,207) (1,744,103)
Receipts fom sales of property, plant and equipment  0  680
 
Net cash from Investing Activities  16,813,541 (11,168,112)
Cash flows from Financing Activities
Repayment of Borrowings  (3,293,332)  (793,332)
Net cash used in Financing Activities  (3,293,332)  (793,332)
 
Net increase/(decrease) in Cash and Cash Equivalents  20,338,622 (7,871,735)
Cash and Cash Equivalents at beginning of year  2,290,820  10,162,555
 
Cash and Cash Equivalents at end of year 9  22,629,442 2,290,820
 
 
Statement of Cash Flows
For the year ended 31 December 2020
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Notes to the Financial Statements
For the year ended 31 December 2020
1. Accounting Policies    
      
A. General information
    
The Health Products Regulatory Authority (HPRA) 
is a public statutory body established under the 
Irish Medicines Board Act 1995 (as amended). The 
principal place of business is at Earlsfort Centre, 
Earlsfort Terrace, Dublin 2. The Health Products 
Regulatory Authority is the competent Authority for 
the regulation of medicines, medical devices and 
other health products in Ireland.    
 
B. Compliance with FRS 102 
The financial statements have been prepared in 
compliance with the applicable legislation, and with 
FRS 102 (the Financial Reporting Standard applicable 
in the UK and the Republic of Ireland), issued by the 
Financial Reporting Council in the UK, as modified 
by the directions of the Minister for Health in relation 
to superannuation. In compliance with the directions 
of the Minister for Health, HPRA accounts for the 
costs of superannuation entitlements only as they 
become payable (see K). This basis of accounting 
does not comply with FRS102, which requires such 
costs to be recognised in the year in which the 
entitlement is earned. The HPRA is availing of the 
reduced disclosures allowed by FRS 102 in relation 
to legal provisions, in instances where full disclosure 
might prejudice seriously its position in relation to 
disputes with other parties on the subject matter 
of the provision. In all other respects, the financial 
statements comply with FRS 102.    
       
    
C. Basis of preparation     
  
The financial statements have been prepared 
under the historical cost convention. The following 
accounting policies have been applied consistently in 
dealing with items which are considered material in 
relation to the Health Products Regulatory Authority’s 
financial statements.     
       
       
     
D. Critical accounting estimates and judgements
      
The preparation of the financial statements requires 
management to make judgements, estimates and 
assumptions that affect the amounts reported for 
assets and liabilities as at the reporting date and 
the amounts reported for revenues and expenses 
during the year. However, the nature of estimation 
means that actual outcomes could differ from those 
estimates. The following may involve a higher degree 
of judgement and complexity: 
  
(a) Provisions     
Provisions for legal obligations which it knows to be 
outstanding at the period-end date. These provisions 
are generally made based on historical or other 
pertinent information, adjusted for recent trends 
where relevant. However, they are estimates of the 
financial costs of events that may not occur for some 
years. As a result of this and the level of uncertainty 
attaching to the final outcomes, the actual outturn 
may differ significantly from that estimated.  
 
(b) Bad and Doubtful Debts   
The HPRA makes an estimate of the recoverable 
value of trade and other receivables. The HPRA 
uses estimates based on historical experience in 
determining the level of bad debts, which the 
Authority believes will not be collected. These 
estimates include such factors as the current credit 
rating, the ageing profile, historical experience of the 
particular trade receivable and objective evidence of 
impairment of the asset. Any significant reduction in 
the level of bad debt provision would have a positive 
impact on the annual surplus/deficit. The level of 
provisioning required is reviewed on an on-going 
basis and has been disclosed in the notes to the 
financial statements.     
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Notes to the Financial Statements
For the year ended 31 December 2020
E. Revenue recognition    
   
Revenue is measured at the fair value of the 
consideration received.    
- In the case of applications for marketing 
authorisations (new applications, variations to 
existing authorisations, or transfers) and clinical trial 
applications, income is recognised on a straight line 
basis over the specified timeline for the processing 
of the application by the Authority.    
- In the case of wholesale and manufacturing licences 
and maintenance of marketing authorisations, fees 
are payable annually and a full year’s income is 
accrued in each financial year.   
        
     
F. Expenditure recognition    
   
Expenditure is recognised in the financial statements 
on an accruals basis.     
       
    
G. Reporting currency and currency 
translation      
 
The financial statements are prepared in euros. 
Transactions in currencies other than euro are 
recorded at the rates ruling at the date of the 
transactions or at a contracted date. Monetary assets 
and liabilities are translated into euro at the reporting 
date or at a contracted date. Exchange differences are 
dealt with in the statement of income and expenditure 
and retained revenue reserves.    
       
       
      
 
       
  
H. Property, plant and equipment   
    
Plant and equipment excluding Premises
Plant and equipment excluding premises are stated at 
cost less accumulated depreciation.
Depreciation is calculated in order to write off the cost 
of property, plant and equipment to their estimated 
residual values over their estimated useful lives by 
equal annual instalments.
The estimated useful lives of property, plant and 
equipment by reference to which depreciation has 
been calculated are as follows:  
Fixtures and Fittings:   5 years  
Computer Equipment :   3 years  
Improvements to Premises :  10 years  
       
   
Premises     
The HPRA purchased its premises at Kevin O’Malley 
House, Earlsfort Centre, Earlsfort Terrace, Dublin 2   
on 22 December 2004. The value capitalised was 
equal to the purchase price plus those costs directly  
attributable to bringing the asset into use. 
No depreciation has been calculated on the value of 
premises, as the remaining useful economic life is   
estimated to be greater than 50 years.   
 
       
I. Taxation      
 
The HPRA is exempt from liability to Corporation Tax 
under Section 227 of the Taxes Consolidation Act, 
1997.       
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Notes to the Financial Statements
For the year ended 31 December 2020
J. Debtors      
 
Known bad debts are written off and specific provision 
is made for any amount the collection of which is 
considered doubtful.      
     
       
K. Superannuation     
  
The superannuation scheme operated by the 
HPRA is in accordance with the Local Government 
(Superannuation Revision) (Consolidation) Scheme, 
1986. It is an unfunded statutory scheme and benefits 
are met from current income as they arise.
The scheme is a defined benefit scheme for 
employees. No provision has been made in respect 
of benefits payable. Pension payments under the 
scheme are charged to the statement of income and 
expenditure when paid. Contributions from employes 
who are members of the scheme are credited to the 
statement of income and expenditure when received. 
The surplus/(deficit) is shown both before and after 
superannuation deductions.
HPRA also operate the Single Public Service Pension 
Scheme. All new entrants into the public sector with 
effect from 1 January 2013 are members of this 
scheme, where all employee pension deductions are 
paid to the Department of Public Expenditure and 
Reform.
By direction of the Minister for Health, no provision 
has been made in respect of benefits payable in 
future years in relation to the Local Government 
(Superannuation Revision) (Consolidation) Scheme 
1986 or the Single Public Service Pension Scheme.
In order to help meet the cost of benefits payable 
in future years, reserves have been split between 
retained reserves and superannuation reserves, which 
consist of employee superannuation contributions. 
Since 2018 the HPRA Audit and Risk Committee have 
also recommended further transfers from retained 
revenue reserves to the superannuation reserve, 
as a result of a number of recent and upcoming 
retirements, where the costs are quite significant. This 
split is shown in note 12 - Movement on Income and 
Expenditure Reserves.     
       
    
       
  
L. Provisions      
 
A provision is recognised when the HPRA has a 
present obligation as a result of a past event, it is 
probable that this will be settled at a cost to the HPRA 
and a reliable estimate can be made of the amount of 
the obligation.  
M. Library      
 
No value has been placed on the books, audio-visual 
resources and electronic databases in the library. 
Expenditure on these items is written off in the year in 
which it is incurred.     
     
       
N. Leases      
 
All leases are treated as operating leases and the 
rentals thereunder are charged to the Statement of  
Income and Expenditure and Retained Revenue 
Reserves on a straight line basis over the lease period.  
       
      
O. Loans      
 
Loans are recognised initially at the transaction price 
(present value of cash payable, including transaction 
costs). Loans are subsequently stated at amortised 
costs. Interest expense is recognised on the basis 
of the effective interest method and is included in 
finance costs.
Loans are classified as current liabilities unless there is 
a right to defer settlement of the loan for at least 12 
months from the reporting date.    
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Notes to the Financial Statements
For the year ended 31 December 2020
2. Property, plant Fixtures and Computer  Leasehold Improvements Premises Total  
 and equipment Fittings Equipment Improvements To Premises    
  € € € € € €
  Cost
  Balance as at     1,323,908 17,713,306 773,461 4,374,608 23,156,037 47,341,320
  1 January 2020  
  Additions for the year              32,139 725,474 92,594  -  -    850,207
  Disposals for the year (35,899) (1,336,989)  -   -     -    (1,372,888)
  As at 31 December 2020        1,320,148 17,101,791 866,055 4,374,608 23,156,037 46,818,639
  Depreciation
  Balance as at     1,234,795 16,565,772 529,547 4,114,752  -  22,444,866
  1 January 2020
  Charge for the year              34,196 926,951 36,360 83,313  - 1,080,820
  Disposals for the year  (35,899) (1,336,989)  -  -  - (1,372,888)
  As at 31 December 2020     1,233,092 16,155,734 565,907  4,198,065  -    22,152,798
  Net Book value at  
 31 December 2020              87,056 946,057 300,148 176,543 23,156,037  24,665,841
  Net Book value at 
  1 January 2020     89,113 1,147,534 243,914 259,856 23,156,037  24,896,454
3.  Income  2020  2019
  €  €
 Fee Income
 Clinical Trials     339,738        389,916   
 Human Medicine - National Fees     6,907,352             7,034,900  
 Human Medicine - European Fees     10,469,002             9,197,663   
 Veterinary Medicine - National Fees     1,930,987             1,988,373   
 Veterinary Medicine - European Fees     2,098,606             1,691,326   
 Compliance Department     5,878,330       5,845,249   
 Medical Devices     1,989,240             1,715,249    
  
     29,613,255           27,862,676   
 Movement in deferred revenue   99,668      70,200  
     29,712,923           27,932,876   
 Dept Of Health Funding (Vote 38 Subhead E1)     4,975,000            4,964,255    
 Other Income (Note 4)     803,196               805,824  
  
 Total Income     35,491,119          33,702,955   
 
Fees received by the Authority under Section 13 of the Irish Medicines Board Act 1995 and Section 29 of the Animal 
Remedies Act 1993, totalling €21,128,900 in 2020, shall be paid into or disposed of for the benefit of the Exchequer in 
such manner as the Minister for Public Expenditure and Reform directs.
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Notes to the Financial Statements
For the year ended 31 December 2020
4.  Other Income
  2020  2019
  €  €
  
 Conference Fee Income    -       12,860   
 Deposit Interest     5,508                  16,737   
 (Loss)/Gain on Disposal of Fixed Assets   -       49 
 IT Income     797,688        714,875   
 Zambia Project Income   -      61,303  
   
    803,196    805,824
5.  Salaries and Wages    
 
 Basic Pay       20,785,092          19,622,110    
 Overtime       9,270               10,956   
 Allowances      190,173          178,300    
 Staff Short Term Benefits      20,984,535          19,811,366    
 Retirement Benefit Costs      1,044,800          1,153,648  
 Employer’s Contribution to Social Welfare      2,123,813          1,986,755   
 Employer’s Contribution to Single Scheme Pension      1,282,977         910,669 
   
        25,436,125           23,862,438  
 
  
The average number of staff employed during the year was 353 (2019 - 348).   
Payroll numbers at 31 December 2020 can be analysed across the following departments:     
   
 
 Chief Executive  4  3
 Compliance  71  63
 Finance, Corporate & International  26  26
 Human Products Authorisation & Registration  105  101
 Human Products Monitoring  35  34
 Human Resources & Change  10  10
 IT & Business Services  17 18
 Medical Devices 43  44
 Quality, Scientific Affairs & Communications 11  12
 Veterinary Sciences  39  35
 Staff  361  346
 Authority Members 5  7
 Pensioners  47  46
  413  399
 
 
No termination or severance payments were made during the year.
Additional superannuation contributions for Public Servants of €644,813 were deducted from staff during the year and 
paid over to the Department of Health. On 1 January 2019, in accordance with DPER circular 21/2018, the pension related 
deduction (PRD) was replaced by an additional superannuation contribution (ASC).
Pension deductions for Public Servants who are members of the Single Public Service Pension Scheme of €432,857 were 
deducted from staff during the year and paid over to the Department of Public Expenditure and Reform. In agreement 
with our parent department and DPER, the HPRA have also paid over Single Scheme employer contributions since 
January 2019 for employees not employed in exchequer funded areas.
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For the year ended 31 December 2020
 Salary Band 2020  2019
 €0 to €60,000  206  214
 €60,001 to €70,000 74  54
 €70,001 to €80,000 19  20
 €80,001 to €90,000    15  16 
 €90,001 to €100,000    21  20 
 €100,001 to €110,000    15  15 
 €110,001 to €120,000    6  4 
 €120,001 to €130,000    4  2 
 €130,001 to €140,000    -  - 
 €140,001 to €150,000    -  -
 €150,001 to €160,000    -  1
 €160,001 to €170,000    1 -  
    361  346 
 Average Salary    €55K  €54.9K 
 
Higher salaries relate primarily to scientific and other professional staff e.g. clinicians, pharmacists, veterinarians, lawyers 
etc and are in accordance with Department of Health salary scales.
For the purposes of this disclosure, short-term employee benefits in relation to services rendered during the reporting 
period include salary, overtime, allowances and other payments made on behalf of the employee, but exclude employer’s 
PRSI.   
  
6.  Operating Costs
  2020  2019
  €  €
  
 Accommodation Costs      1,498,976         1,291,822   
 Travel, Representation and Training     365,503         973,179  
 Bank Charges and Interest     353,621          179,047   
 Legal Fees    147,150          2,344,387   
 Audit Fees (External and Internal)     34,323          34,305   
 Stationery, Publications, Postage and Communications      336,144          464,148    
 Consultancy      332,980          499,038    
 Sampling and Analysis     240,179                       243,132   
 IT Costs     1,591,951                      1,342,133   
 Document Storage     124,379                       152,279    
 Telephone and Telecommunications     107,972                       97,616    
 Movement on Bad Debt Provision     (74,160)                  18,287   
   
    5,059,018                 7,639,373   
  
Travel costs include an amount of €23,792 related to staff hospitality, and an amount of €80,697 related to travel and 
subsistence, of which €69,854 is national and €10,843 is foreign. 
No costs were incurred in relation to client hospitality.
Legal fees are in relation to ongoing legal proceedings, and do not include any amounts in relation to conciliation, 
arbitration or settlement payments.
Consultancy costs comprise €173,142 related to public relations/marketing, €125,735 related to human resources/
pensions and €34,103 related to other.   
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Employee’s short term benefits are categorised into the following bands:
Notes to the Financial Statements
For the year ended 31 December 2020
7.  Debtors (all due within one year) 2020  2019
  €  €
 
 Trade Debtors     2,505,431        2,018,140   
 Prepayments    244,562                     309,093   
 Other Debtors     96,268        187,751   
   
     2,846,261        2,514,984  
Trade debtors are shown net of the bad debt provision.
8. Creditors (amounts falling due within one year)   
 
 
 Trade Creditors     402,819                    1,174,870  
 Credit Balances on Debtor Accounts  5,570,223 3,180,518
 Accruals     5,506,511        5,512,384   
 Deferred Revenue     1,638,629                  1,738,297   
 Revenue Commissioners                696,243                    687,018    
  
           13,814,425                  12,293,087   
9. Cash and Cash Equivalents    
  
  
 Cash at Bank and in Hand        10,472,026     772,549 
 Demand Deposits (Convertible to Cash on Demand)        12,157,416          1,518,271 
 
              22,629,442          2,290,820   
 
10. Short Term Deposits     
 
 
 Short Term Deposits (not immediately convertible to cash)    -            17,658,240   
  
           -              17,658,240   
 
11. Administration Expenses    
 
 Surplus for the year was calculated having charged:    
 Auditor’s Remuneration   20,000   20,000 
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12.   Movement on Income and  
    Expenditure Reserves 
      Transfer  
    As At Income & to Superann As At 
    01/01/2020  Expenditure  Reserve  31/12/2020 
     € € € € 
  
  Retained Reserves     19,138,266 3,915,156  (2,000,000)  21,053,422   
Superannuation Reserve  11,967,998 637,287 2,000,000 14,605,285    
 
          31,106,264  4,552,443 0  35,658,707    
Our Audit and Risk Committee recommended the transfer of a further €2,000,000 in 2020 from retained revenue 
reserves to the superannuation reserve as a result of a number of recent and upcoming retirements, where the costs are 
quite significant.    
 
13. Long Term Liabilities   
    
  Mortgage
On 22 December 2004 the HPRA purchased its premises at Kevin O’Malley House, Earlsfort Centre, Earlsfort Terrace, 
Dublin 2. The purchase was financed by way of a mortgage, secured on the premises of €20,400,000 over 20 years from 
Bank of Ireland Corporate Lending.
The HPRA is committed to making the following capital repayments on its mortgage:   
     
    
 
  2020  2019
      €  € 
 
  - within one year              168,337                793,332 
  - between one and five years           505,011              3,173,328  
  - after five years     -             20  
   
         673,348        3,966,680   
 On 30 December 2020 the HPRA made a partial redemption of its mortgage with Bank of Ireland, paying €2,500,000 
off the outstanding balance. This will result in lower quarterly repayment amounts over the remaining 4 years of the 
mortgage.     
 
14. Interest Rate Exposure   
 
The HPRA have taken all necessary steps to minimise its interest rate exposure by fixing 2/3s of the borrowings for the 
mortgage duration. The balance of the borrowings are fully offset by cash reserves. As the mortgage is at a fixed rate, 
the Authority has no interest rate exposure.     
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15. Financial Commitments
 Accommodation Costs (Note 6) includes expenditure of €645,106 in relation to operating leases. 
 On 28 January 2005 the HPRA signed a leasehold interest in respect of the 5th floor, 6 Earlsfort Terrace, Dublin 2.  
 At 31 December 2020 this lease had 1 year and 4 months remaining.   
    
    
  2020  2019
   €  €
 The amounts due under this lease are as follows:
 - within one year  285,984   285,984
 - between one and five years     95,328        381,312   
 - after five years  -   -
   
     381,312         667,296   
On 11 June 2019 the HPRA signed a leasehold interest in respect of the 4th floor, 6 Earlsfort Terrace, Dublin 2.  
The lease included a 7 month rent free period to 10 January 2020. 
At 31 December 2020 this lease had 13 years and 5.5 months remaining.  
 
   
 The amounts due under this lease are as follows:
 - within one year    365,246      360,735 
 - between one and five years      1,460,983         1,485,683  
 - after five years    3,089,372      3,508,230 
   
      4,915,601          5,354,648  
16. Capital Commitments   
     
 Contracted For (Contract Signed)       20,963       26,779  
 Contracted For ( Contract Not Signed )       93,436      -  
   
       114,399       26,779   
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17. Authority Remuneration Fees  Expenses
   €  €
  
 Ann Horan (Chairperson)           11,970               - 
 Joe Collins              2,012                  -
 David Holohan            7,695                 450 
 Brian Jones          7,695               989 
 Elizabeth Keane             7,695                 171
 David Kerins           -               164
 Caitriona O’Driscoll  - 264
 Diarmuid Quinlan             7,695                 - 
 Richard Reilly            -                 - 
   
      44,762         2,038  
Up to the 15th February 2017, other than the Chairperson, no other Authority Member received a salary. On 16th 
February 2017, the Health (Miscellaneous Provisions) Act was enacted, which made provision for payment of fees to 
other Authority members, provided that they were in compliance with the ‘one person one salary’ principle. Three 
Authority members do not receive a fee under this principle.
Authority expenses comprise €1,049 domestic and €989 foreign.  
 
18. Key Management Personnel Remuneration 2020  2019
  €  €
    
 Chief Executive   160,524   157,031
 Senior Management   940,884     812,419 
   
      1,101,408         969,450   
  
  
All payments to key management personnel were in respect of salaries and short term employee benefits. No post-
employment benefits or termination benefits were paid.
The Chief Executive’s and senior management’s pension entitlements do not extend beyond the standard entitlements 
in the model public sector defined benefit superannuation scheme.   
   
  
19. Related Party Transactions
  
The HPRA adopts procedures in accordance with the guidelines issued by the Department of Public Expenditure and 
Reform (DPER) covering the personal interests of Authority members. A register of such interests is maintained. In 
addition to the DPER guidelines, as a regulator the HPRA has strict conflict of interest and disclosure requirements in 
relation to any interactions with a regulated body, which are updated annually. There have been no transactions with 
related parties which require disclosure under Financial Reporting Standard 102.   
   
20. Prompt Payment of Accounts
  
 The Health Products Regulatory Authority (HPRA) confirms that it is complying with EU law in relation to prompt 
payment of accounts.     
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21. Exchange Rates
  
 The exchange rates used in preparing these financial statements were as follows: 
  2020 €1 = STG £0.90453
 2019 €1 = STG £0.85369
22. Provisions
 
The HPRA has been notified of a number of legal proceedings or potential proceedings. The Authority has provided 
in full for its ‘best estimate’ of the expenditure it is likely to incur in relation to those cases. The Authority is availing of 
the reduced disclosures allowed by FRS 102 in instances where full disclosure might prejudice seriously its position in a 




The HPRA has a reasonable expectation, at the time of approving the financial statements, that the HPRA has adequate 
resources to continue its operations. For this reason, the HPRA continues to adopt the going concern basis in preparing 
the financial statements.
The COVID-19 pandemic has impacted how the HPRA operates, with all staff substantially moved offsite and resources 
diverted to managing implications of the pandemic. The Authority assesses this event to be a non-adjusting post 
balance sheet event in relation to the 2020 financial results. No impact is expected in relation to the 2020 financial 
statements and currently we are not predicting a significant financial impact for 2021, although due to the nature of 
the pandemic, the final impact cannot be estimated at this point. HPRA’s income is derived from the pharmaceutical, 
medical devices and related industries, which continue to operate throughout the pandemic and therefore are 
financially less impacted than those industries which have closed or have limited output.   
      
     
 
24. Approval of Financial Statements
  
 The financial statements were approved by the Authority of the HPRA on 24 June 2021.
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Educational/Professional Development Presentations and Training 
Institution Course Presentation Title
DCU Bioprocess Engineering Regulation of Biologicals
DCU Bioprocess Engineering Regulation of Medicines
DCU Chemistry Regulatory Affairs and Risk 
Management 
Irish Defence Forces Training Workshop The Role of the HPRA and Safety 
Monitoring of Medicines 
LAST Ireland Training Workshop Implementation of Directive 2010/63/
EU in Ireland
Letterkenny IT Seminar Regulation of Veterinary Medicinal 
Products in Ireland 
Maynooth University Immunology and Global Health Regulation of Medicines
RCSI Pharmacy Regulation of Medicines, From 
Discovery to Commercial Product; 
Non-Clinical Pharmacology and 
Toxicology
RCSI Nurse/Midwife Prescribing The Role of the HPRA and 
Pharmacovigilance
RCSI Pharmacy Overview of Pharmacovigilance
St Johns College, Cork Seminar Regulation of vmps in  Ireland 
TCD Pharmaceutical Medicine Early Access to Medicines
TCD Pharmaceutical Medicine The Centralised Procedure & 
Overview of CHMP
TCD Pharmaceutical Medicine The Work of EMA’s Scientific Advice 
Working Party
TCD Pharmaceutical Medicine Nonclinical drug development
TCD Pharmaceutical Medicine Committee for Orphan Medicinal 
Products (COMP)
TCD Pharmaceutical Medicine Communication of Drug Safety Data 
& Overview of the WHO Programme 




TCD Pharmaceutical Medicine Collection and reporting of adverse 
events/reaction reports arising from 
Clinical Trials 
TCD Immunotherapeutics Regulation of Biologicals
TCD Immunotherapeutics Biological Medicinal Products
TCD Immunotherapeutics Regulation of Medicines
TCD Pharmaceutical Medicine The role of the Co-ordination 
group for Mutual recognition and 
Decentralised procedures – human 
(CMDh)
TCD Immunology Regulation of Medicines
TCD Pharmaceutical Medicine Medicines Regulation: 
International Quality Standards and 
Pharmacopoeias 
TCD Pharmaceutical Manufacturing 
Technology
The HPRA and the Role of the 
Pharmacopoeia in the regulation of 
medicines
TCD Pharmacy Overview of Pharmacovigilance 
TOPRA Training Workshop The SmPC - A  Regulator’s 
Perspective
UCC Medicine/Pharmacy Notification of Adverse Reactions
UCD Biotechnology Regulation of Clinical Trials
UCD Biotechnology Regulation of Biological Medicines
UL Regulatory Affairs (Bio) 
Pharmaceuticals
Compiling a Successful Clinical Trial 
Application - The Agency Viewpoint
UL Regulatory Affairs (Bio) 
Pharmaceuticals
Fundamentals of Pharmaceutical 
Development
UL Regulatory Affairs (Bio) 
Pharmaceuticals
The Future of Regulation and Lessons 
Learned during COVID-19
76
APPENDIX 2 – HPRA Annual Report 2020
77
APPENDIX 2 – HPRA Annual Report 2020
Event/Organiser Presentation Title
5th EFSPI Workshop on Regulatory Statistics Regulatory Update on Estimands
EMA Workshop Article 117 - The Notified Body Opinion - An 
Assessor's View
EMA Workshop Implementation of MDR on drug-device 
combinations
EMA Workshop Update on the DDC guideline
PDA Regulatory advances - new technologies and Industry 
4.0
CASSS CMC Forum Europe 2020 ICH Q13 - Short Update
Biopharma Ambition ATMPs - the Regulatory Perspective
TOPRA Conference Module 3: An Agency Perspective
PMI The HPRA and COVID
EMeRGE conference Optimising safe and effective use of medicines
Klifovet AG Safety requirements for veterinary medicinal products
17th Munich Workshop on VICH Good Clinical 
Practice and efficacy studies in animals
The regulatory view in the assessment of clinical 
efficacy of Veterinary Medicinal Products
17th Munich Workshop on VICH Good Clinical 
Practice and efficacy studies in animals
Benefit-risk balance: the assessment of authorities
European Commission - DG Environment - Development of NTS Guidance
HPRA Webinar Series HPRA November Webinar Series: Implementation of 
MDR and IVDR
EMA/DIA ICSR Data Quality and Impact on Data Analysis and 
Safety Monitoring
EMeRGE Conference Health Products Regulation - Optimising safe and 
effective use of medicines
DIA Europe Experience of HPRA in European Medicines 
Regulatory Network
HCRI Regulatory Support for COVID-19 Vaccine 
Development and PPI







– Ulipristal acetate 5mg (Esmya) for uterine fibroids – suspension of marketing authorisation 
during ongoing review of liver injury risk
– Paracetamol – reminder to prescribers on risk of hepatotoxicity in patients with risk 
factors
– Durvalumab (Imfinzi ) – risk of myasthenia gravis
– Rivaroxaban (Xarelto) – not for use as thromboprophylaxis in patients who have recently 
undergone transcatheter aortic valve replacement
– Selective Serotonin Reuptake Inhibitors (SSRI) and Serotonin-norepinephrine reuptake 
inhibitors (SNRI) – persistent sexual dysfunction after drug withdrawal
– Direct Healthcare Professional Communications published on the HPRA website since the 
last Drug Safety Newsletter
– DHPC appended due to limitations resultant from the COVID-19 pandemic:  Direct 
Healthcare Professional Communication: Restrictions in use of cyproterone acetate due 
to risk of meningioma
May 
97th Edition
– Teratogenicity of valproate-containing medicines (Epilim ) – Reminder of important 
restrictions for use in women and girls
May 
98th Edition
– Adverse reaction reporting during the COVID-19 pandemic – reminder
– Picato (ingenol mebutate) – EMA review concludes negative benefit risk balance due to 
risk of skin malignancy
– Levetiracetam – risk of abnormal and aggressive behaviours
– Cyproterone acetate – restrictions in use due to risk of meningioma
– Carbimazole and propylthiouracil – use in pregnancy and in women of childbearing 
potential
– Carbimazole – risk of acute pancreatitis
– Testosterone-containing medicinal products: caution in patients with thrombophilia or risk 
factors for venous thromboembolism (VTE)
– Direct Healthcare Professional Communications published on the HPRA website since the 
last Drug Safety Newsletter
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September 
99th Edition
– Erythromycin – Updated warnings regarding cardiovascular risks and infantile 
hypertrophic pyloric stenosis
– Vascular Endothelial Growth Factor (VEGF) pathway inhibitors – Risk of aneurysm and 
artery dissection
– Implanon NXT (etonogestrel implant) – Updated insertion and removal instructions due 
to risk of neurovascular injury and implant migration
– Insulin-containing medicines – Risk of cutaneous amyloidosis and potential for associated 
changes in glycaemic control
– Leuprorelin-containing depot medicines – Risk of lack of efficacy due to incorrect 
reconstitution and administration
– Xeljanz (tofacitinib) – Updated recommendations due to increased risk of venous 
thromboembolism and serious and fatal infections
– Risk of respiratory depression and sedation associated with Epaclob 1mg/ml and 2mg/ml 
oral suspension (clobazam)
– Direct Healthcare Professional Communications published on the HPRA website since the 
last Drug Safety Newsletter
November 
100th Edition
– Introductory article written by the Pharmacovigilance Manager, Ms Niamh Arthur, on the 
occasion of the 100th edition of the DSN
– Optimising safe and effective use of medicines in clinical practice through proactive risk 
management
– Adverse reaction reporting
– Product information for medicines
– Registering with the HPRA for safety alerts and updates
Veterinary Medicines Articles – External Publications 
Month Publication Topic
March Veterinary Ireland Journal Why is the HPRA changing the method of supply of 
antiparasitic veterinary medicinal products?
July Veterinary Ireland Journal Veterinary Antibiotics – Future European Developments
January It’s Your Field HPRA review of antiparasitic veterinary medicinal products 
used in food-producing animals
March It’s Your Field Classification of borderline products by the HPRA
July It’s Your Field How the HPRA regulates veterinary medicines
September It’s Your Field Implementation of the HPRA report on the change to 
prescription control in respect of antiparasitic veterinary 
medicinal products 
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Committee/Working Group Organisation Meetings 
in 2020
Counterfeiting of Medical Products (CMED) Council of Europe 2
EU Veterinary Medicines Regulation Department of 
Agriculture, Food and 
the Marine
3
iNAP (Ireland’s National Action Plan on AMR) Animal Health 
Implementation Committee
Department of 
Agriculture, Food and 
the Marine
4
Blood & Organ Transplant and Acute Hospital Service Planning 
Policy Unit
Department of Health 1
Children and Family Relationships Act Department of Health 3
Connecting for Life Strategy Department of Health 1
Controlled Drugs Cross Border Group Department of Health 2
Early Warning and Emerging Trends Group Department of Health 3
National Public Health Emergency Team – COVID-19 Department of Health 63
Committee for Cosmetics and Consumer Health EDQM 1
Committee for Cosmetics and Consumer Health and European 
Network of OCCLs – Joint meeting
EDQM 2
EDQM Committee Meetings EDQM 8
European Pharmacopoeia Commission EDQM 3
National Pharmacopoeia Authorities – Annual Meeting EDQM 2
OMCL Network Active Pharmaceutical Ingredient (API) Working 
Group
EDQM 2
OMCL Network Advisory Group EDQM 5
OMCL Network Centrally Authorised Products (CAP) Working 
Group
EDQM 1
OMCL Network Communications Working Group EDQM 1
OMCL Network Mutual Recognition and Decentralised procedures 
(MRP/DCP) Working Group
EDQM 1
Biological Working Party EMA 11
Biosimilar Medicines Working Party (BMWP) EMA 5
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Committee/Working Group 
Participation
Committee/Working Group Organisation Meetings 
in 2020
Committee for Advanced Therapies (CAT) EMA 11
Committee for Herbal Medicinal Products (HMPC) EMA 6
Committee for Medicinal Products for Human Use (CHMP) EMA 11
Committee for Medicinal Products for Veterinary Use (CVMP) EMA 11
Committee for Orphan Medicinal Products (COMP) EMA 11
COVID-19 EMA Pandemic Task Force EMA 2 meetings 
per week
Good Clinical Practice (GCP) Inspectors’ Working Group (including 
training seminar)
EMA 13
Good Manufacturing and Distribution Practice (GMDP) Inspectors’ 
Working Group
EMA 4
Management Board EMA 4
Paediatric Committee (PDCO) EMA 11
Pharmacovigilance (PV) Inspectors’ Working Group (human & 
veterinary)
EMA 4
Pharmacovigilance Risk Assessment Committee (PRAC) EMA 11
Pharmacovigilance Working Party - Veterinary EMA 6
Quality Defects and Rapid Alert Working Group EMA 4
Quality Review of Documents Working Groups EMA 3
Quality Working Party EMA 4
Rapid Alert Network re Nitrosamines EMA 4
Safety Working Party - Human EMA 13
Safety Working Party – Veterinary EMA 1
Sartans Lessons Learned Group EMA 2
Scientific Advice Working Party - Human EMA 11
Signal Management Review Technical Working Group (Methods) – 
PRAC
EMA 4
Signal Management Review Technical Working Group (SMART) 
Processes – PRAC
EMA 5
Veterinary Medicines Regulation – Drafting of implementing acts EMA 8
Working Group on Revision of ICH Q9 Guideline EMA & ICH 19
Competent Authorities for Organ Donation and Transplantation European Commission 1
Competent Authorities for Tissues and Cells European Commission 3
Competent Authorities on Blood and Blood Components European Commission 2
Expert Group on Clinical Trials European Commission 4
Expert Sub-Group on Vigilance for Blood, Tissues and Cells, and 
Organs (VES)
European Commission 1
Expert Working Group on Safety Features (including meetings, 
telecons & workshop with EMVO)
European Commission 3
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in 2020
Expert Working Group on Safety Features (including meetings, 
telecons & workshop with European Medicines Verification 
Organisation)
European Commission 3
Joint Action Market Surveillance of Medical Devices European Commission 3
Medical Device Coordination Group (MDCG) (MDR/IVDR) European Commission 8
MDCG - Notified Body Oversight (NBO) European Commission 2
MDCG - International matters European Commission 2
MDCG - In Vitro Diagnostic (IVD) European Commission 1
MDCG - Nomenclature European Commission 1
MDCG - Annex XVI European Commission 2
MDCG - Standards European Commission 1
MDCG - Clinical Investigation and Evaluation (CIE) - Including 
Monthly Teleconference
European Commission 10
MDCG - Market Surveillance and Vigilance (PMSV) European Commission 2
MDCG - Borderline and Classification European Commission 1
MDCG - Unique Device Identification (UDI) European Commission 1
MDCG - New Technologies (NT) European Commission 1
MDCG - EUDAMED by videoconference European Commission 2
MDCG - Unique Device Identification (UDI) European Commission 2
National Contact Points for the Implementation of Directive 
2010/63/EU
European Commission 1
Pharmaceutical Committee European Commission 7
Platform of European Market Surveillance Activities in Cosmetics 
(PEMSAC) – Market Surveillance
European Commission 1
Standing Committee on Cosmetic Products European Commission 3
Standing Committee on Veterinary Medicinal Products European Commission 4
Sub-group on borderline issues relating to cosmetics European Commission 2
Working Group on Cosmetic Products European Commission 5
Working Group on Good Distribution Practice for Active 
Pharmaceutical Ingredients and Veterinary Medicinal Products
European Commission 1
Working Group on Guidance for the Completion of Non-technical 
Project Summaries
European Commission 3
Interpretation Guide for Harmonised Assessment Checklist for 
Audits of GMP Inspectorates
European Commission 
/ EMA / HMA / PIC/S
1
Authorisation of Preparation Process for blood, tissues and cells 
(GAPP Work Package Five, Six and Seven)
European Commission 
/ National Competent 
Authorities
14
Inspections Expert Subgroup (IES) Work Cluster IV (Blood, Tissues 
and Organs)
European Commission 
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Committee/Working Group Organisation Meetings 
in 2020
Operational/Liaison meeting Europol 10
Food Fraud Task Force Food Safety Authority 
of Ireland (FSAI)
1
Clinical Trials Facilitation Group (CTFG) HMA 7
CMDh/GCP Inspectors Sub-Group HMA 2
Co-ordination Group for Mutual Recognition and Decentralised 
procedures – Human (CMDh)
HMA 11
Co-ordination Group for Mutual Recognition and Decentralised 
procedures – Veterinary (CMDv)
HMA 11
EU Innovation Network HMA 7
Heads of Agency Meeting HMA 4
Homeopathic Medicinal Products Working Group HMA 1
Pharmacovigilance Worksharing Procedures Working Party HMA 11
Risk Assessment tool for surveillance testing HMA 1
Risk-based Surveillance Testing – Drafting Group (including 
telecons)
HMA 1
Working Group of Communications Professionals HMA 2
Working Group of Enforcement Officers (WGEO) (including 
management committee)
HMA 7
Working Group of Quality Managers HMA 2
ICMRA Plenary Meeting ICMRA 50
International Coalition of Medicines Regulatory Authorities 
(ICMRA) – Pharmacovigilance group
ICMRA 3
International Coalition of Medicines Regulatory Authorities 
(ICMRA) - Vaccine Confidence Working Group
ICMRA 3
International Medical Device Regulators Forum (IMDRF) 
Management Committee
IMDRF 2




Permanent forum on International Pharmaceutical Crime (PFIPC) PFIPC 2
Pharmaceutical Inspection Co-Operation Scheme (PIC/S) 
Executive Bureau
PIC/S 1
PIC/S Executive Bureau PIC/S 1
PIC/S Expert Circle on Quality Risk Management (QRM) PIC/S 20
PIC/S Strategic Roadmap Working Group PIC/S 1
PIC/S Sub-Committee on Harmonisation PIC/S 4
PIC/S sub-committee on Training PIC/S 2
National Immunisation Advisory Committee (NIAC) Royal College of 
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